<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1124" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1124/" /><meta name="ncbi_pagename" content="Noonan Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Noonan Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Noonan Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/08/08" /><meta name="citation_author" content="Judith E Allanson" /><meta name="citation_author" content="Amy E Roberts" /><meta name="citation_pmid" content="20301303" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/" /><meta name="citation_keywords" content="Dual specificity mitogen-activated protein kinase kinase 1" /><meta name="citation_keywords" content="GTPase KRas" /><meta name="citation_keywords" content="GTPase NRas" /><meta name="citation_keywords" content="GTP-binding protein Rit1" /><meta name="citation_keywords" content="Leucine-zipper-like transcriptional regulator 1" /><meta name="citation_keywords" content="RAF proto-oncogene serine/threonine-protein kinase" /><meta name="citation_keywords" content="Serine/threonine-protein kinase B-raf" /><meta name="citation_keywords" content="Son of sevenless homolog 1" /><meta name="citation_keywords" content="Tyrosine-protein phosphatase non-receptor type 11" /><meta name="citation_keywords" content="BRAF" /><meta name="citation_keywords" content="KRAS" /><meta name="citation_keywords" content="LZTR1" /><meta name="citation_keywords" content="MAP2K1" /><meta name="citation_keywords" content="NRAS" /><meta name="citation_keywords" content="PTPN11" /><meta name="citation_keywords" content="RAF1" /><meta name="citation_keywords" content="RIT1" /><meta name="citation_keywords" content="SOS1" /><meta name="citation_keywords" content="Noonan Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Noonan Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Judith E Allanson" /><meta name="DC.Contributor" content="Amy E Roberts" /><meta name="DC.Date" content="2019/08/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/" /><meta name="description" content="Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population." /><meta name="og:title" content="Noonan Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1124/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/noonan/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1124/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A427DE04095610000000001A00096.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1124_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1124_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rp-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/leopard/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1124_"><span class="title" itemprop="name">Noonan Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Judith E Allanson</span>, MD and <span itemprop="author">Amy E Roberts</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1124_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1124_ai__"><div class="contrib half_rhythm"><span itemprop="author">Judith E Allanson</span>, MD<div class="affiliation small">Department of Genetics<br />Children's Hospital of Eastern Ontario<br />Ottawa, Ontario, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.no.oehc@nosnalla" class="oemail">ac.no.oehc@nosnalla</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amy E Roberts</span>, MD<div class="affiliation small">Cardiovascular Genetics<br />Children's Hospital Boston<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.notsobhc.oidrac@strebor.yma" class="oemail">gro.notsobhc.oidrac@strebor.yma</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 15, 2001</span>; Last Revision: <span itemprop="dateModified">August 8, 2019</span>.</p><p><em>Estimated reading time: 49 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="noonan.Summary" itemprop="description"><h2 id="_noonan_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Noonan syndrome (NS) is characterized by characteristic facies, short stature, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>NS is diagnosed on clinical grounds by observation of key features. Affected individuals have normal <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> studies. Molecular genetic testing identifies a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PTPN11</i> in 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, <i>SOS1</i> in approximately 13%, <i>RAF1</i> and <i>RIT1</i> each in 5%, and <i>KRAS</i> in fewer than 5%. Other reported genes &#x02013; in which pathogenic variants have been found to cause Noonan syndrome in fewer than 1% of cases &#x02013; include <i>BRAF</i>, <i>LZTR1</i>, <i>MAP2K1</i>, and <i>NRAS</i>. Several additional genes associated with a Noonan-syndrome-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in fewer than ten individuals have been identified.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Cardiovascular anomalies in NS are usually treated as in the general population. Developmental disabilities are addressed by early intervention programs and individualized education strategies. Treatment for serious bleeding is guided by knowledge of the specific factor deficiency or platelet aggregation anomaly. Growth hormone (GH) treatment increases growth velocity.</p><p><i>Surveillance:</i> Monitoring of anomalies found in any system, especially cardiovascular abnormalities.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>NS is most often inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. While many individuals with autosomal dominant NS have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent is recognized in 30%-75% of families. The risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with autosomal dominant NS depends on the genetic status of the parents: if a parent is affected, the risk is 50%; when the parents are clinically unaffected, the risk to the sibs of a proband appears to be low (&#x0003c;1%). Each child of an individual with autosomal dominant Noonan syndrome has a 50% chance of inheriting the pathogenic variant. NS caused by pathogenic variants in <i>LZTR1</i> can be inherited in either an autosomal dominant or an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The parents of an individual with autosomal recessive NS are typically heterozygotes (i.e., have one <i>LZTR1</i> pathogenic variant), and may either be asymptomatic or have mild features of NS. If both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for one <i>LZTR1</i> pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of having one <i>LZTR1</i> pathogenic variant (which can be associated with mild NS features), and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>. Prenatal testing is possible if the NS-related pathogenic variant(s) have been identified in an affected family member.</p></div></div><div id="noonan.Diagnosis"><h2 id="_noonan_Diagnosis_">Diagnosis</h2><div id="noonan.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Noonan syndrome (NS) <b>should be suspected</b> in individuals with the following key features:</p><ul><li class="half_rhythm"><div class="half_rhythm">Characteristic facies. The facial appearance of NS shows considerable change with age, being most striking in young and middle childhood, and most subtle in the adult. Key features found irrespective of age include low-set, posteriorly rotated ears with fleshy helices; vivid blue or blue-green irises; and eyes that are often wide-spaced, downslanted, and with epicanthal folds and fullness or droopiness of the upper eyelids (ptosis).</div><div class="half_rhythm"><b>Note:</b> See the National Human Genome Research Institute (NHGRI) <a href="https://research.nhgri.nih.gov/atlas/condition/noonan-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Atlas of Human Malformation Syndromes</a> (scroll to <b>ATLAS IMAGES</b>) for photographs of individuals with Noonan syndrome from diverse ethnic backgrounds.</div></li><li class="half_rhythm"><div class="half_rhythm">Short stature</div></li><li class="half_rhythm"><div class="half_rhythm">Congenital heart defect, most commonly pulmonary valve stenosis, atrial septal defect, and/or hypertrophic cardiomyopathy</div></li><li class="half_rhythm"><div class="half_rhythm">Developmental delay of variable degree</div></li><li class="half_rhythm"><div class="half_rhythm">Broad or webbed neck</div></li><li class="half_rhythm"><div class="half_rhythm">Unusual chest shape with superior pectus carinatum, inferior pectus excavatum</div></li><li class="half_rhythm"><div class="half_rhythm">Widely set nipples</div></li><li class="half_rhythm"><div class="half_rhythm">Cryptorchidism in males</div></li><li class="half_rhythm"><div class="half_rhythm">Other:</div><ul><li class="half_rhythm"><div>Coagulation defects. Coagulation screens (e.g., prothrombin time, activated partial thromboplastin time, platelet count, and bleeding time) may show abnormalities. Specific testing should identify the particular coagulation defect, such as von Willebrand disease, thrombocytopenia, varied coagulation factor defects (factors V, VIII, XI, XII, protein C), and platelet dysfunction.</div></li><li class="half_rhythm"><div>Lymphatic dysplasias of the lungs, intestines, and/or lower extremities</div></li></ul></li></ul><p>Diagnostic criteria developed by van der Burgt in 1997 were published in <a class="bk_pop" href="#noonan.REF.van_der_burgt.2007.4">van der Burgt [2007]</a>. While they have not been used extensively in North America, they are of particular value in the research <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, and are embedded in <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">management guidelines</a> developed by Dyscerne in the United Kingdom [<a class="bk_pop" href="#noonan.REF1">Noonan Syndrome Guideline Development Group 2010</a>]. This clinical management guideline also provides details of recommended baseline investigations and age-specific management. Similar recommendations are provided in <a class="bk_pop" href="#noonan.REF.romano.2010.746">Romano et al [2010]</a> and <a class="bk_pop" href="#noonan.REF.roberts.2013.333">Roberts et al [2013]</a>.</p></div><div id="noonan.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of NS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes listed in <a class="figpopup" href="/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fignoonanTmoleculargenetictestingused" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a> or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LZTR1</i> idenfitied by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Testing approaches can include use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes the genes listed in <a class="figpopup" href="/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fignoonanTmoleculargenetictestingused" rid-ob="figobnoonanTmoleculargenetictestingused">Table1</a> and other genes of interest (see <a href="#noonan.Differential_Diagnosis">Differential Diagnosis</a>) is the test of choice for an individual suspected of having Noonan syndrome. Because of significant phenotypic overlap with cardiofaciocutaneous syndrome and Costello syndrome, most available panels include the genes for these diagnoses, too. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> can be considered if panel testing is not feasible. Approximately 50% of individuals with NS have a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant in <i>PTPN11</i>; therefore, single-gene testing starting with <i>PTPN11</i> would be the next best first test. Appropriate serial single-gene testing if <i>PTPN11</i> testing is not diagnostic can be determined by the individual's <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (e.g., <i>RIT1</i> if there is hypertrophic cardiomyopathy, <i>SHOC2</i> if there is a loose anagen hair phenotype, <i>LZTR1</i> if <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance is suspected); however, continued sequential single-gene testing is not recommended as it is more costly than panel testing.</div><div class="half_rhythm">Since Noonan syndrome occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism and large intragenic deletions or duplications have not been reported, testing for intragenic deletions or duplications is unlikely to result in a diagnosis; however, rare cases have been reported for some genes (see <a class="figpopup" href="/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="fignoonanTmoleculargenetictestingused" rid-ob="figobnoonanTmoleculargenetictestingused">Table 1</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> or <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> and/or serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing fails to confirm a diagnosis in an individual with features of NS.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="noonan.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Noonan Syndrome (NS)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of NS Attributed to Pathogenic Variants in Gene</th><th id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Method</th></tr><tr><th headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PTPN11</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%&#x000a0;<sup>5</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nearly 100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rare <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>,&#x000a0;<sup>6</sup> diagnosis of NS questioned&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SOS1</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-13%&#x000a0;<sup>8</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAF1</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>10</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nearly 100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">One reported case w/a <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>,&#x000a0;<sup>11</sup> diagnosis of NS questioned&#x000a0;<sup>7</sup><br />One reported case of a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>&#x000a0;<sup>12</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RIT1</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>10</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>KRAS</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5%&#x000a0;<sup>13</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NRAS</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8 individuals &#x00026; 4 families&#x000a0;<sup>14</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BRAF</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>15</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAP2K1</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>16</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LZTR1</i></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>17</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Others&#x000a0;<sup>18</sup></td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_noonan.T.molecular_genetic_testing_used_1_1_1_3 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_1 hd_h_noonan.T.molecular_genetic_testing_used_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="noonan.TF.1.1"><p class="no_margin">See <a href="/books/NBK1124/#noonan.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="noonan.TF.1.2"><p class="no_margin">See <a href="#noonan.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="noonan.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="noonan.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="noonan.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.tartaglia.2002.1555">Tartaglia et al [2002]</a></p></div></dd><dt>6. </dt><dd><div id="noonan.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.shchelochkov.2008.1042">Shchelochkov et al [2008]</a>, <a class="bk_pop" href="#noonan.REF.graham.2009.2122">Graham et al [2009]</a>, <a class="bk_pop" href="#noonan.REF.chen.2014a.28">Chen et al [2014a]</a></p></div></dd><dt>7. </dt><dd><div id="noonan.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.lissewski.2015.2685">Lissewski et al [2015]</a></p></div></dd><dt>8. </dt><dd><div id="noonan.TF.1.8"><p class="no_margin">Approximately 16%-20% of individuals with a clinical diagnosis of Noonan syndrome who do not have an identified <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are found to have an <i>SOS1</i> pathogenic variant [<a class="bk_pop" href="#noonan.REF.roberts.2007.70">Roberts et al 2007</a>, <a class="bk_pop" href="#noonan.REF.tartaglia.2007.75">Tartaglia et al 2007</a>].</p></div></dd><dt>9. </dt><dd><div id="noonan.TF.1.9"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>10. </dt><dd><div id="noonan.TF.1.10"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.aoki.2016.33">Aoki et al [2016]</a></p></div></dd><dt>11. </dt><dd><div id="noonan.TF.1.11"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.luo.2012.1918">Luo et al [2012]</a></p></div></dd><dt>12. </dt><dd><div id="noonan.TF.1.12"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.sana.2014.2069">Sana et al [2014]</a></p></div></dd><dt>13. </dt><dd><div id="noonan.TF.1.13"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.schubbert.2006.331">Schubbert et al [2006]</a>, <a class="bk_pop" href="#noonan.REF.brasil.2010.425">Brasil et al [2010]</a></p></div></dd><dt>14. </dt><dd><div id="noonan.TF.1.14"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.de_filippi.2009.706">De Filippi et al [2009]</a>, <a class="bk_pop" href="#noonan.REF.cirstea.2010.27">Cirstea et al [2010]</a>, <a class="bk_pop" href="#noonan.REF.runtuwene.2011.393">Runtuwene et al [2011]</a>, <a class="bk_pop" href="#noonan.REF.denayer.2012.34">Denayer et al [2012]</a>, <a class="bk_pop" href="#noonan.REF.kraoua.2012.2407">Kraoua et al [2012]</a>, <a class="bk_pop" href="#noonan.REF.ekvall.2015.95">Ekvall et al [2015]</a></p></div></dd><dt>15. </dt><dd><div id="noonan.TF.1.15"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al [2009]</a></p></div></dd><dt>16. </dt><dd><div id="noonan.TF.1.16"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.nava.2007.763">Nava et al [2007]</a></p></div></dd><dt>17. </dt><dd><div id="noonan.TF.1.17"><p class="no_margin"><a class="bk_pop" href="#noonan.REF.yamamoto.2015.413">Yamamoto et al [2015]</a>, <a class="bk_pop" href="#noonan.REF.johnston.2018.1175">Johnston et al [2018]</a>, <a class="bk_pop" href="#noonan.REF.jacquinet.2019">Jacquinet et al [2019]</a>, <a class="bk_pop" href="#noonan.REF.nakaguma.2019.260">Nakaguma et al [2019]</a>, <a class="bk_pop" href="#noonan.REF.pagnamenta.2019.693">Pagnamenta et al [2019]</a>, <a class="bk_pop" href="#noonan.REF.perin.2019">Perin et al [2019]</a>, <a class="bk_pop" href="#noonan.REF.umeki.2019.21">Umeki et al [2019]</a></p></div></dd><dt>18. </dt><dd><div id="noonan.TF.1.18"><p class="no_margin">Recent reports have implicated several additional genes associated with a Noonan syndrome-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in fewer than ten individuals each including <i>RRAS</i> (2 probands) [<a class="bk_pop" href="#noonan.REF.flex.2014.4315">Flex et al 2014</a>], <i>RASA2</i> (3 probands) [<a class="bk_pop" href="#noonan.REF.chen.2014b.11473">Chen et al 2014b</a>], <i>A2ML1</i> (3 probands) [<a class="bk_pop" href="#noonan.REF.vissers.2015.317">Vissers et al 2015</a>], <i>SOS2</i> (8 probands) [<a class="bk_pop" href="#noonan.REF.cordeddu.2015.1080">Cordeddu et al 2015</a>, <a class="bk_pop" href="#noonan.REF.yamamoto.2015.413">Yamamoto et al 2015</a>], and <i>MRAS</i> (5 probands) [<a class="bk_pop" href="#noonan.REF.higgins.2017.e91225">Higgins et al 2017</a>, <a class="bk_pop" href="#noonan.REF.motta.2019.1007">Motta et al 2019</a>, <a class="bk_pop" href="#noonan.REF.suzuki.2019.1628">Suzuki et al 2019</a>].</p></div></dd></dl></div></div></div></div></div><div id="noonan.Clinical_Characteristics"><h2 id="_noonan_Clinical_Characteristics_">Clinical Characteristics</h2><div id="noonan.Clinical_Description"><h3>Clinical Description</h3><p><b>Prenatal features.</b> Advanced paternal age has been observed in cohorts with <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> NS [<a class="bk_pop" href="#noonan.REF.tartaglia.2004a.492">Tartaglia et al 2004a</a>]. Common perinatal findings include: polyhydramnios; lymphatic dysplasia including increased nuchal translucency and cystic hygroma; relative macrocephaly; and cardiac and renal anomalies [<a class="bk_pop" href="#noonan.REF.myers.2014.2814">Myers et al 2014</a>]. In chromosomally normal fetuses with increased nuchal translucency, it is estimated that 5%-15% have <i>PTPN11</i>-associated NS [<a class="bk_pop" href="#noonan.REF.bakker.2014.355">Bakker et al 2014</a>].</p><p><b>Growth.</b> Birth weight is usually normal, although edema may cause a transient increase. Infants with NS frequently have feeding difficulties. This period of failure to thrive is self-limited, although poor weight gain may persist for up to 18 months.</p><p>Length at birth is usually normal. Postnatal growth failure is often obvious from the first year of life [<a class="bk_pop" href="#noonan.REF.otten.2009.31">Otten &#x00026; Noordam 2009</a>]. Mean height then follows the third centile from ages two to four years until puberty, when below-average growth velocity and an attenuated adolescent growth spurt tend to occur. As bone maturity is usually delayed, prolonged growth into the 20s is possible.</p><p>Final adult height approaches the lower limit of normal: 161-167 cm in males and 150-155 cm in females. Growth curves have been developed from these cross-sectional retrospective data. One study suggests that 30% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have height within the normal adult range, while more than 50% of females and nearly 40% of males have an adult height below the third centile [<a class="bk_pop" href="#noonan.REF.noonan.2003.68">Noonan et al 2003</a>].</p><p>Decreased IGF-I- and IGF-binding protein 3, together with low responses to provocation, suggest impaired growth hormone release, or disturbance of the growth hormone / insulin-like growth factor I axis, in many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons. Mild growth hormone resistance related to a post-receptor signaling defect, which may be partially compensated for by elevated growth hormone secretion, is reported in individuals with NS and a <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#noonan.REF.binder.2005.5377">Binder et al 2005</a>]. See <a href="#noonan.Management">Management</a> for discussion of growth hormone (GH) treatment.</p><p><b>Cardiovascular.</b> Significant bias in the frequency of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart disease may exist because many clinicians have in the past required the presence of cardiac anomalies for diagnosis of NS. The frequency of congenital heart disease is estimated at between 50% and 80%.</p><ul><li class="half_rhythm"><div><b>Pulmonary valve</b>
<b>stenosis,</b> often with dysplasia, is the most common anomaly in NS, found in 20%-50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; it may be <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> or associated with other cardiovascular defects.</div></li><li class="half_rhythm"><div><b>Hypertrophic cardiomyopathy</b> is found in 20% to 30% of individuals with NS. It usually presents early in life: the median age at diagnosis is five months and more than 50% of individuals with NS and hypertrophic cardiomyopathy are diagnosed by age six months [<a class="bk_pop" href="#noonan.REF.hickey.2011.41">Hickey et al 2011</a>, <a class="bk_pop" href="#noonan.REF.wilkinson.2012.442">Wilkinson et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Other structural defects</b> frequently observed include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Coarctation of the aorta is more common than previously thought [<a class="bk_pop" href="#noonan.REF.noonan.2005b.177">Noonan 2005b</a>].</div></li><li class="half_rhythm"><div><b>An electrocardiographic abnormality</b> is documented in approximately 90% of individuals with NS and may be present without concomitant structural defects. Extreme right axis deviation with superior counterclockwise frontal QRS loop, superior or left axis deviation, or left anterior hemiblock or an RSR' pattern in lead V1 are common findings [<a class="bk_pop" href="#noonan.REF.sharland.1992.178">Sharland et al 1992</a>].</div></li></ul><p><b>Psychomotor development.</b> Early developmental milestones may be delayed, likely in part as a result of the combination of joint hyperextensibility and hypotonia. The average age for sitting unsupported is around ten months and for walking is 21 months [<a class="bk_pop" href="#noonan.REF.sharland.1992.178">Sharland et al 1992</a>]. About 50% of school-age children meet diagnostic criteria for a developmental coordination disorder [<a class="bk_pop" href="#noonan.REF.lee.2005a.35">Lee et al 2005a</a>] and impaired manual dexterity is significantly correlated with verbal and nonverbal intellectual functioning [<a class="bk_pop" href="#noonan.REF.pierpont.2009.275">Pierpont et al 2009</a>].</p><p>Most school-age children perform well in a normal educational setting, but 25% have learning disabilities [<a class="bk_pop" href="#noonan.REF.lee.2005a.35">Lee et al 2005a</a>] and 10%-15% require special education [<a class="bk_pop" href="#noonan.REF.van_der_burgt.1999.707">van der Burgt et al 1999</a>]. Intellectual abilities are, in general, mildly lowered in children with NS. IQ scores below 70 are seen in 6%-23% across studies [<a class="bk_pop" href="#noonan.REF.van_der_burgt.1999.707">van der Burgt et al 1999</a>, <a class="bk_pop" href="#noonan.REF.pierpont.2015.385">Pierpont et al 2015</a>]. Studies conflict with regard to strength in verbal vs nonverbal performance and no clear pattern has emerged [<a class="bk_pop" href="#noonan.REF.lee.2005a.35">Lee et al 2005a</a>, <a class="bk_pop" href="#noonan.REF.pierpont.2009.275">Pierpont et al 2009</a>]. There may be a specific cognitive disability, either in verbal or praxic reasoning, requiring a special academic strategy and school placement.</p><p>Articulation deficiency is common (72%) but usually responds well to speech therapy. Language delay may be related to hearing loss, perceptual motor disabilities, or articulation deficiencies. The average age at first words is around 15 months and simple two-word phrases emerge on average from age 31 to 32 months [<a class="bk_pop" href="#noonan.REF.pierpont.2010a.591">Pierpont et al 2010a</a>].</p><p>A study of the language <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of children and adults with NS showed that language impairments in general are more common in NS than in the general population and, when present, are associated with a higher risk for reading and spelling difficulties [<a class="bk_pop" href="#noonan.REF.pierpont.2010b.917">Pierpont et al 2010b</a>]. Language is significantly correlated with nonverbal cognition, hearing ability, articulation, motor dexterity, and phonologic memory. No specific aspect of language was selectively <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in those with NS.</p><p>There is emerging evidence that attention and executive functioning are one of the most common neuropsychological challenges for children with NS [<a class="bk_pop" href="#noonan.REF.pierpont.2015.385">Pierpont et al 2015</a>]. Studies that rely on screening measures rather than comprehensive diagnostic assessments suggest that children with NS are at heightened risk for autism spectrum disorders; however, further research is needed [<a class="bk_pop" href="#noonan.REF.pierpont.2016">Pierpont 2016</a>].</p><p><b>Psychological health.</b> Few details of psychological health in Noonan syndrome are reported. No particular syndrome of behavioral disability or psychopathology is observed, and self-esteem is comparable to age-related peers [<a class="bk_pop" href="#noonan.REF.lee.2005a.35">Lee et al 2005a</a>]. <a class="bk_pop" href="#noonan.REF.noonan.a">Noonan [2005a]</a> has documented problems in a cohort of 51 adults: depression was found in 23%, and occasional substance abuse and bipolar disease was reported. Similar findings were not reported in a large UK cohort followed over many years [<a class="bk_pop" href="#noonan.REF.shaw.2007.128">Shaw et al 2007</a>].</p><p>Detailed psychological assessment of a group of 11 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals identified anxiety, panic attacks, social introversion, impoverished self-awareness, and marked difficulties in identifying and expressing feelings and emotions (alexithymia) [<a class="bk_pop" href="#noonan.REF.verhoeven.2008.191">Verhoeven et al 2008</a>]. This same research team suggests that in adulthood mild problems in attention, organizational skills, psychosocial immaturity, and alexithymia may be found, and thus assessment of social cognition and personality may be appropriate [<a class="bk_pop" href="#noonan.REF.wingbermuehle.2009.15">Wingbermuehle et al 2009</a>]. In one study of adults with NS, 49% reported that they had been diagnosed and treated for depression and/or anxiety [<a class="bk_pop" href="#noonan.REF.smpokou.2012.3106">Smpokou et al 2012</a>].</p><p><b>Genitourinary.</b> Renal abnormalities, generally mild, are present in 11% of individuals with NS. Dilatation of the renal pelvis is most common. Duplex collecting systems, minor rotational anomalies, distal ureteric stenosis, renal hypoplasia, unilateral renal agenesis, unilateral renal ectopia, and bilateral cysts with scarring are reported less commonly.</p><p>Male pubertal development and subsequent fertility may be normal, delayed, or inadequate. Deficient spermatogenesis may be related to cryptorchidism, which is noted in 60% to 80% of males; however, a study of male gonadal function identified Sertoli cell dysfunction in males with cryptorchidism and those with normal testicular descent, suggesting an intrinsic defect leading to hypergonadotropic hypogonadism [<a class="bk_pop" href="#noonan.REF.marcus.2008.1079">Marcus et al 2008</a>].</p><p>Puberty may be delayed in females, with a mean age at menarche of 14.6&#x000b1;1.17 years. Normal fertility is the rule.</p><p><b>Facial features.</b> Differences in facial appearance, albeit subtle at certain ages, are a key clinical feature:</p><ul><li class="half_rhythm"><div><b>In the neonate,</b> tall forehead, hypertelorism with downslanting palpebral fissures, low-set, posteriorly rotated ears with a thickened helix, a deeply grooved philtrum with high, wide peaks to the vermilion border of the upper lip, and a short neck with excess nuchal skin and low posterior hairline are found.</div></li><li class="half_rhythm"><div><b>In infancy,</b> eyes are prominent, with horizontal palpebral fissures, hypertelorism, and full or ptotic upper eyelids. The nose has a depressed root, wide base, and bulbous tip.</div></li><li class="half_rhythm"><div><b>In childhood,</b> facial appearance is often lacking in affect or expression, as in an individual with a myopathy.</div></li><li class="half_rhythm"><div><b>By adolescence,</b> facial shape is an inverted triangle, wide at the forehead and tapering to a pointed chin. Eyes are less prominent and features are sharper. The neck lengthens, accentuating skin webbing or prominence of the trapezius muscle.</div></li><li class="half_rhythm"><div><b>In the older adult,</b> nasolabial folds are prominent, and the skin appears transparent and wrinkled.</div></li></ul><p><b>Bleeding diathesis.</b> Most persons with NS have a history of abnormal bleeding or bruising. Early studies reported that about one third of all individuals with NS have one or more coagulation defects with subsequent studies suggesting a lower rate of coagulopathy [<a class="bk_pop" href="#noonan.REF.derbent.2010.2768">Derbent et al 2010</a>]. The coagulopathy may manifest as severe surgical hemorrhage, clinically mild bruising, or laboratory abnormalities with no clinical consequences. A variety of small studies have shown that while 50%-89% of those with NS have either a history of bleeding and/or abnormal hemostatic lab results, only 10%-42% have both [reviewed in <a class="bk_pop" href="#noonan.REF.briggs.2012.167">Briggs &#x00026; Dickerman 2012</a>].</p><p><b>Lymphatic.</b> Varied lymphatic abnormalities are described in individuals with NS. They may be localized or widespread, prenatal, and/or postnatal. Dorsal limb (top of the foot and back of the hand) lymphedema is most common. Less common findings include: intestinal, pulmonary, or testicular lymphangiectasia; chylous effusions of the pleural space and/or peritoneum; and localized lymphedema of the scrotum or vulva.</p><p>Prenatal features suggestive of Noonan syndrome, likely of a lymphatic nature, include: transient or persistent cystic hygroma, polyhydramnios, and (rarely) hydrops fetalis [<a class="bk_pop" href="#noonan.REF.gandhi.2004.183">Gandhi et al 2004</a>, <a class="bk_pop" href="#noonan.REF.yoshida.2004b.63">Yoshida et al 2004b</a>, <a class="bk_pop" href="#noonan.REF.jo_.2005.373">Jo&#x000f3; et al 2005</a>].</p><p><b>Ocular.</b> Ocular abnormalities including strabismus, refractive errors, amblyopia, and nystagmus occur in up to 95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Anterior segment and fundus changes are less common. There are case reports of keratoconus and axenfeld anomaly [<a class="bk_pop" href="#noonan.REF.lee.2014.1171">Lee &#x00026; Sakhalkar 2014</a>, <a class="bk_pop" href="#noonan.REF.guerin.2015.403">Guerin et al 2015</a>].</p><p><b>Dermatologic.</b> Skin differences, particularly follicular keratosis over extensor surfaces and face, are relatively common and may occasionally be as severe as those found in <a href="/books/n/gene/cfc/">cardiofaciocutaneous syndrome</a> (see <a href="#noonan.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Caf&#x000e9; au lait spots and lentigines are described in NS more frequently than in the general population (see Noonan syndrome with multiple lentigines discussion in <a href="#noonan.Genetically_Related_Allelic_Disor">Genetically Related Disorders</a>).</p><p><b>Other</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Arnold-Chiari I malformation.</b> Eleven cases of Arnold-Chiari malformation have been reported in the medical literature, although the true incidence in NS is not known [<a class="bk_pop" href="#noonan.REF.keh.2013.749">Keh et al 2013</a>, <a class="bk_pop" href="#noonan.REF.mitsuhara.2014.6">Mitsuhara et al 2014</a>, <a class="bk_pop" href="#noonan.REF.zarate.2014.np13">Zarate et al 2014</a>, <a class="bk_pop" href="#noonan.REF.ejarque.2015.408">Ejarque et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hepatosplenomegaly</b> is frequent; the cause is likely related to subclinical myelodysplasia.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Juvenile myelomonocytic leukemia (JMML).</b> Individuals with Noonan syndrome and a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PTPN11</i> have a predisposition to this unusual childhood leukemia. In general, JMML in Noonan syndrome runs a more benign course.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Other malignancies.</b> One study of individuals with Noonan syndrome caused by a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PTPN11</i> supports a threefold increased risk of malignancy [<a class="bk_pop" href="#noonan.REF.jongmans.2011.870">Jongmans et al 2011</a>].</div><ul><li class="half_rhythm"><div>Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are found at higher frequency in Noonan syndrome than in the general population [<a class="bk_pop" href="#noonan.REF.hasle.2009.8">Hasle 2009</a>, <a class="bk_pop" href="#noonan.REF.jongmans.2011.870">Jongmans et al 2011</a>].</div></li><li class="half_rhythm"><div>Solid tumors, such as rhabdomyosarcoma and neuroblastoma, are described [<a class="bk_pop" href="#noonan.REF.denayer.2010.242">Denayer et al 2010</a>, <a class="bk_pop" href="#noonan.REF.jongmans.2010.635">Jongmans et al 2010</a>]. Three embryonal rhabdomyosarcomas (ERMS) caused by a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SOS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported [<a class="bk_pop" href="#noonan.REF.denayer.2010.242">Denayer et al 2010</a>, <a class="bk_pop" href="#noonan.REF.hastings.2010.967">Hastings et al 2010</a>, <a class="bk_pop" href="#noonan.REF.jongmans.2010.635">Jongmans et al 2010</a>]. One with obstructive jaundice involved the biliary ampulla/duodenum; one the bladder; and one the urachus. Three additional cases of ERMS and NS (of the orbit, vagina, and abdomen) were reported; <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> was not determined [<a class="bk_pop" href="#noonan.REF.khan.1995.743">Khan et al 1995</a>, <a class="bk_pop" href="#noonan.REF.jung.2003.330">Jung et al 2003</a>, <a class="bk_pop" href="#noonan.REF.moschovi.2007.341">Moschovi et al 2007</a>].</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Overall risk of malignancy.</b> Kratz et al reported on a cohort of 632 individuals with molecularly confirmed NS (inclusive of Noonan syndrome with multiple lentigines) and found four cases of JMML, two of brain tumor, two of ALL, and one neuroblastoma, and calculated a childhood cancer standardized incidence ratio of 8.1 [<a class="bk_pop" href="#noonan.REF.kratz.2015.1392">Kratz et al 2015</a>]. Individuals with NS are at an eightfold greater risk of developing a childhood cancer than are those without NS.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Myeloproliferative disorders,</b> either transient or more fulminant, can also occur in infants with Noonan syndrome [<a class="bk_pop" href="#noonan.REF.kratz.2005.2183">Kratz et al 2005</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Noonan-like / multiple giant-cell lesion syndrome.</b> The giant-cell granulomas and bone and joint anomalies in Noonan-like / multiple giant-cell lesion syndrome are recognized to be part of the Noonan syndrome spectrum. They can resemble cherubism, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder caused by pathogenic variants in <i>SH3BP2</i> (see <a href="/books/n/gene/cherubism/">Cherubism</a>), lesions observed in neurofibromatosis (see <a href="/books/n/gene/nf1/">Neurofibromatosis Type 1</a>), or lesions observed in the Ramon syndrome with juvenile rheumatoid arthritis (polyarticular pigmented villonodular synovitis).</div><div class="half_rhythm">Noonan-like / multiple giant-cell lesion syndrome is caused by pathogenic variants in <i>PTPN11</i> [<a class="bk_pop" href="#noonan.REF.jafarov.2005.190">Jafarov et al 2005</a>, <a class="bk_pop" href="#noonan.REF.wolvius.2006.1289">Wolvius et al 2006</a>] and <i>SOS1</i> [<a class="bk_pop" href="#noonan.REF.beneteau.2009.1216">Beneteau et al 2009</a>, <a class="bk_pop" href="#noonan.REF.neumann.2009.420">Neumann et al 2009</a>]. One family with Noonan-like / multiple giant-cell lesion syndrome has a <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> reported in Noonan syndrome without giant cell lesions [<a class="bk_pop" href="#noonan.REF.tartaglia.2002.1555">Tartaglia et al 2002</a>]; thus, additional genetic factors may be necessary for the giant cell proliferation to occur.</div><div class="half_rhythm">These multiple giant cell lesions are also recognized in persons with <a href="/books/n/gene/cfc/">cardiofaciocutaneous syndrome</a> caused by mutation of <i>BRAF</i> and <i>MEK1</i> [<a class="bk_pop" href="#noonan.REF.neumann.2009.420">Neumann et al 2009</a>]. Thus dysregulation of the RAS-MAPK pathway represents the common and basic molecular event predisposing to giant-cell lesion formation, arguing against the existence of Noonan-like / multiple giant-cell lesion syndrome as a separate entity.</div></li></ul></div><div id="noonan.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b><i>PTPN11</i>.</b> Analysis of a large cohort of individuals with Noonan syndrome (NS) [<a class="bk_pop" href="#noonan.REF.tartaglia.2001.465">Tartaglia et al 2001</a>, <a class="bk_pop" href="#noonan.REF.tartaglia.2002.1555">Tartaglia et al 2002</a>] has suggested that <i>PTPN11</i> pathogenic variants are more likely to be found when pulmonary stenosis is present, whereas hypertrophic cardiomyopathy is less prevalent among individuals with NS caused by <i>PTPN11</i> abnormalities.</p><p>Additional cohort analyses have linked <i>PTPN11</i> pathogenic variants to short stature, pectus deformity, easy bruising, characteristic facial appearance [<a class="bk_pop" href="#noonan.REF.yoshida.2004a.3359">Yoshida et al 2004a</a>, <a class="bk_pop" href="#noonan.REF.zenker.2004.368">Zenker et al 2004</a>], and cryptorchidism [<a class="bk_pop" href="#noonan.REF.jongmans.2004.56">Jongmans et al 2004</a>]. In contradistinction, the study of <a class="bk_pop" href="#noonan.REF.allanson.2010.1960">Allanson et al [2010]</a> failed to establish any facial <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> correlation.</p><p>The presence or absence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PTPN11</i> does not affect the likelihood of developmental delay, although individuals with the <a class="figpopup" href="/books/NBK1124/table/noonan.T.selected_ptpn11_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="fignoonanTselectedptpn11pathogenicvari" rid-ob="figobnoonanTselectedptpn11pathogenicvari">p.Asn308Asp</a> pathogenic variant are said to be more likely to receive normal education [<a class="bk_pop" href="#noonan.REF.jongmans.2004.56">Jongmans et al 2004</a>].</p><p>Germline pathogenic variants at codons 61, 71, 72, and 76 are significantly associated with leukemogenesis and identify a subgroup of individuals with NS at risk for JMML [<a class="bk_pop" href="#noonan.REF.niihori.2005.192">Niihori et al 2005</a>].</p><p>The post-receptor signaling defect causing mild growth hormone resistance in individuals with NS and a <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#noonan.REF.binder.2005.5377">Binder et al 2005</a>] leads to reduced efficacy of short-term growth hormone (GH) treatment in individuals with a <i>PTPN11</i> pathogenic variant [<a class="bk_pop" href="#noonan.REF.binder.2005.5377">Binder et al 2005</a>, <a class="bk_pop" href="#noonan.REF.ferreira.2005.5156">Ferreira et al 2005</a>, <a class="bk_pop" href="#noonan.REF.limal.2006.300">Limal et al 2006</a>]. However, careful review of height data reveals that individuals with a <i>PTPN11</i> pathogenic variant presented with more severe short stature and, therefore, reached a lower final height despite a similar height gain [<a class="bk_pop" href="#noonan.REF.noordam.2008.203">Noordam et al 2008</a>].</p><p>An <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> three-nucleotide <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (p.Gly60del) in a female infant with severe features of Noonan syndrome, including hydrops fetalis and juvenile myelomonocytic leukemia [<a class="bk_pop" href="#noonan.REF.yoshida.2004a.3359">Yoshida et al 2004a</a>], has been reported. The <a class="figpopup" href="/books/NBK1124/table/noonan.T.selected_ptpn11_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="fignoonanTselectedptpn11pathogenicvari" rid-ob="figobnoonanTselectedptpn11pathogenicvari">p.Asp61del</a> three-nucleotide <i>PTPN11</i> deletion has also been reported in a child with typical rather than severe NS [<a class="bk_pop" href="#noonan.REF.lee.2005b.7">Lee et al 2005b</a>].</p><p><b><i>SOS1</i>.</b>
<a class="bk_pop" href="#noonan.REF.tartaglia.2007.75">Tartaglia et al [2007]</a> concluded that the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in 22 individuals with NS who had an <i>SOS1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> fell within the spectrum of NS, but emphasized the more frequent occurrence of ectodermal abnormalities and a greater likelihood of normal development and stature in these individuals compared to others with NS. In a companion paper, <a class="bk_pop" href="#noonan.REF.roberts.2007.70">Roberts et al [2007]</a> reported that 14 individuals with NS who had a <i>SOS1</i> pathogenic variant did not differ in development and stature from other individuals with NS. Cardiac septal defects were found more frequently than in individuals with NS and pathogenic variants in <i>PTPN11</i>. The study did not make specific mention of ectodermal findings.</p><p><a class="bk_pop" href="#noonan.REF.pierpont.2009.275">Pierpont et al [2009]</a> have studied intellectual abilities in Noonan syndrome and report that individuals with <i>SOS1</i> pathogenic variants generally have average or higher-level skills.</p><p><b><i>RAF1</i>.</b> Studies emphasize a striking correlation with hypertrophic cardiomyopathy, with 95% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <i>RAF1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> showing this feature, in comparison with the overall prevalence in NS of 18%. This suggests that pathologic cardiomyocyte hypertrophy occurs because of increased RAS signaling. Multiple nevi, lentigines, and/or caf&#x000e9; au lait spots were reported in one third of people with <i>RAF1</i>-associated NS.</p><p><b><i>KRAS</i>.</b> The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with pathogenic variants in <i>KRAS</i> tends to be atypical, with greater likelihood and severity of intellectual disability [<a class="bk_pop" href="#noonan.REF.zenker.2007.131">Zenker et al 2007</a>] in these individuals than in others with NS. <a class="bk_pop" href="#noonan.REF.kratz.2009.1036">Kratz et al [2009]</a> reported the somewhat unusual feature of craniosynostosis in two unrelated probands with NS and a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>KRAS</i> variant.</p><p><b><i>NRAS</i>.</b> Few individuals with an <i>NRAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been reported. The clinical features appear to be typical with no particular or distinctive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> observed [<a class="bk_pop" href="#noonan.REF.cirstea.2010.27">Cirstea et al 2010</a>].</p><p><b><i>BRAF, MAP2K1</i>.</b> The rare individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BRAF</i> or <i>MAP2K1</i> also appear to have features of classic Noonan syndrome, albeit with florid ectodermal manifestations [<a class="bk_pop" href="#noonan.REF.nava.2007.763">Nava et al 2007</a>, <a class="bk_pop" href="#noonan.REF.nystr_m.2008.500">Nystr&#x000f6;m et al 2008</a>, <a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al 2009</a>].</p><p><b><i>RIT1.</i></b> Compared to the prevalence of hypertrophic cardiomyopathy overall in NS (20%), there is an overrepresentation of HCM in individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RIT1</i> (70%-75%) [<a class="bk_pop" href="#noonan.REF.aoki.2013.173">Aoki et al 2013</a>, <a class="bk_pop" href="#noonan.REF.yaoita.2016.209">Yaoita et al 2016</a>]. Analysis of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals also suggests a high prevalence of perinatal abnormalities, high birth weight, relative macrocephaly, curly hair, hyperpigmentation, and wrinkled palms and soles but lower prevalence of short stature, pectus deformity, or intellectual disability [<a class="bk_pop" href="#noonan.REF.bertola.2014.2952">Bertola et al 2014</a>, <a class="bk_pop" href="#noonan.REF.yaoita.2016.209">Yaoita et al 2016</a>].</p><p><b><i>LZTR1</i>.</b> Overall, the features reported in individuals with NS caused by either <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LZTR1</i> are those commonly seen in individuals with NS of other genetic causes, including typical facial features, pulmonary valve stenosis, hypertrophic cardiomyopathy, short stature, and developmental delay. A more in-depth evaluation of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of those with a heterozygous <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or biallelic pathogenic variants in <i>LZTR1</i> suggests increased prevalence of hypertrophic cardiomyopathy in those with biallelic pathogenic variants (19/26 with biallelic pathogenic variants vs 5/26 with a heterozygous pathogenic variant) [<a class="bk_pop" href="#noonan.REF.pagnamenta.2019.693">Pagnamenta et al 2019</a>].</p></div><div id="noonan.Penetrance"><h3>Penetrance</h3><p>Penetrance of NS is difficult to determine because of ascertainment bias and <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> with frequent subtlety of features. Many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> adults are diagnosed only after the birth of a more obviously affected infant.</p></div><div id="noonan.Nomenclature"><h3>Nomenclature</h3><p>An early term for NS, "male Turner syndrome," incorrectly implied that the condition would not be found in females.</p><p>In 1949, Otto Ullrich reported <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and noted a similarity between their features and those in a strain of mice bred by Bonnevie (webbed neck and lymphedema). The term "Bonnevie-Ullrich syndrome" became popular, particularly in Europe.</p></div><div id="noonan.Prevalence"><h3>Prevalence</h3><p>NS is common and reported to occur in between 1:1,000 and 1:2,500 persons. Mild expression is likely to be overlooked.</p></div></div><div id="noonan.Genetically_Related_Allelic_Disor"><h2 id="_noonan_Genetically_Related_Allelic_Disor_">Genetically Related (Allelic) Disorders</h2><p><b><i>PTPN11</i></b></p><ul><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/leopard/">Noonan syndrome with multiple lentigines</a> (formerly LEOPARD syndrome: lentigines, ECG abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities of genitalia, retardation of growth, deafness) is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition with variable expression. It shows significant overlap with Noonan syndrome (NS), in which pigmentary findings such as nevi (25%), caf&#x000e9; au lait patches (10%), and lentigines (3%) are reported. In early childhood the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of LEOPARD syndrome can be typical of Noonan syndrome; however, with age other characteristic features including lentigines and hearing loss develop. Inheritance is autosomal dominant.</div><div class="half_rhythm">Pathogenic variants in <i>PTPN11</i> and <i>RAF1</i> are identified in about 93% of individuals with LEOPARD syndrome; two individuals were found to have a <i>BRAF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#noonan.REF.koudova.2009.337">Koudova et al 2009</a>, <a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Noonan-like / multiple giant-cell lesion syndrome (see <a href="#noonan.Clinical_Description">Clinical Description</a>)</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> band 12q24.1-q24.23, the region that includes <i>PTPN11</i>, may cause a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar or identical to Noonan syndrome, presumably as a result of increased <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> dosage [<a class="bk_pop" href="#noonan.REF.shchelochkov.2008.1042">Shchelochkov et al 2008</a>, <a class="bk_pop" href="#noonan.REF.graham.2009.2122">Graham et al 2009</a>, <a class="bk_pop" href="#noonan.REF.lissewski.2015.2685">Lissewski et al 2015</a>].</div></li></ul><p><b><i>KRAS</i>.</b> In rare cases mutation of <i>KRAS</i> is associated with <a href="/books/n/gene/cfc/">cardiofaciocutaneous syndrome</a> (see <a href="#noonan.Differential_Diagnosis">Differential Diagnosis</a>).</p><p><b><i>SOS1</i>.</b> A <a class="def" href="/books/n/gene/glossary/def-item/frameshift-variant/">frameshift variant</a> in <i>SOS1</i> has been reported in a single four-generation family with hereditary gingival fibromatosis [<a class="bk_pop" href="#noonan.REF.hart.2002.943">Hart et al 2002</a>]. This condition is a rare form of gingival overgrowth characterized by benign slowly progressive fibrous enlargement of the maxillary and mandibular keratinized gingiva. <i>SOS1</i> pathogenic variants have not been reported in other families with this disorder.</p><p><b><i>RAF1</i>.</b>
<a href="/books/n/gene/leopard/">Noonan syndrome with multiple lentigines</a> (LEOPARD syndrome) is also caused by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>RAF1</i>. About one third of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families without <i>PTPN11</i> pathogenic variants have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RAF1</i>.</p><p>In rare cases <i>RAF1</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are observed in somatic cancer (see <a class="bk_pop" href="#noonan.REF.pandit.2007.1007">Pandit et al [2007]</a>, references).</p><p><b><i>BRAF.</i></b> Germline pathogenic variants in <i>BRAF</i> are usually found in <a href="/books/n/gene/cfc/">cardiofaciocutaneous syndrome</a>.</p><p><b><i>MEK1.</i></b> Germline pathogenic variants in <i>MEK1</i> are a common cause of <a href="/books/n/gene/cfc/">cardiofaciocutaneous syndrome</a>.</p><p><b><i>LZTR1</i>.</b> Constitutional <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> pathogenic variants in <i>LZTR1</i> cause <a href="/books/n/gene/schwann/">schwannomatosis</a> type 2 [<a class="bk_pop" href="#noonan.REF.piotrowski.2014.182">Piotrowski et al 2014</a>], typically characterized by the development of multiple subcutaneous and peripheral nerve schwannomas, or less commonly, meningiomas [<a class="bk_pop" href="#noonan.REF.jacquinet.2019">Jacquinet et al 2019</a>].</p><p><a href="#noonan.Cancer_and_Benign_Tumors"><b>Cancer and benign tumors</b></a><b>.</b> Sporadic tumors (including leukemia and solid tumors) occurring as single tumors in the absence of any other findings of Noonan syndrome may harbor somatic nucleotide variants in <i>PTPN11</i>, <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>MAP2K1</i>, or <i>LZTR1</i> that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; thus, predisposition to these tumors is not heritable.</p></div><div id="noonan.Differential_Diagnosis"><h2 id="_noonan_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Turner syndrome,</b> found only in females, is differentiated from Noonan syndrome (NS) by demonstration of a sex <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> abnormality on <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> studies in individuals with Turner syndrome. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of Turner syndrome is actually quite different from that of NS, when one considers face, heart, development, and kidneys. In Turner syndrome, renal anomalies are more common, developmental delay is much less frequently found, and left-sided heart defects are the rule.</p><p>Like NS, <b>Watson syndrome</b> (OMIM <a href="http://omim.org/entry/193520" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">193520</a>) is characterized by short stature, pulmonary valve stenosis, variable intellectual development, and skin pigment changes (e.g., caf&#x000e9; au lait patches). The Watson syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> also overlaps with that of <a href="/books/n/gene/nf1/">neurofibromatosis 1</a>; the two are now known to be allelic [<a class="bk_pop" href="#noonan.REF.allanson.1991.752">Allanson et al 1991</a>].</p><p><a href="/books/n/gene/cfc/"><b>Cardiofaciocutaneous (CFC) syndrome</b></a> and NS have the greatest overlap in features. CFC syndrome has similar cardiac and lymphatic findings [<a class="bk_pop" href="#noonan.REF.noonan.2001">Noonan 2001</a>, <a class="bk_pop" href="#noonan.REF.armour.2008.249">Armour &#x00026; Allanson 2008</a>]. In CFC syndrome, intellectual disability is usually more severe, with a higher likelihood of structural central nervous system anomalies; skin pathology is more florid; gastrointestinal problems are more severe and long lasting; and bleeding diathesis is rare. Facial appearance tends to be coarser, dolichocephaly and absent eyebrows are more frequently seen, and blue eyes are less commonly seen. To date, the four genes in which mutation is known to cause CFC syndrome are <i>BRAF</i> (~75%), <i>MAP2K1</i> and <i>MAP2K2</i> (~25%), and <i>KRAS</i> (&#x0003c;2%-3%). Rarely, individuals have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> usually associated with Noonan syndrome [<a class="bk_pop" href="#noonan.REF.narumi.2008.834">Narumi et al 2008</a>, <a class="bk_pop" href="#noonan.REF.nystr_m.2008.500">Nystr&#x000f6;m et al 2008</a>].</p><p><a href="/books/n/gene/costello/"><b>Costello syndrome</b></a> shares features with both NS and CFC [<a class="bk_pop" href="#noonan.REF.hennekam.2003.42">Hennekam 2003</a>, <a class="bk_pop" href="#noonan.REF.gripp.2006.1">Gripp et al 2006</a>, <a class="bk_pop" href="#noonan.REF.kerr.2006.401">Kerr et al 2006</a>]. Many individuals with Costello syndrome have been studied molecularly; no <i>PTPN11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified [<a class="bk_pop" href="#noonan.REF.tartaglia.2003a.423">Tartaglia et al 2003a</a>, <a class="bk_pop" href="#noonan.REF.tr_ger.2003.82">Tr&#x000f6;ger et al 2003</a>]. Germline pathogenic variants occurring most commonly in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 of the <i>HRAS</i> proto-oncogene have been shown to cause Costello syndrome [<a class="bk_pop" href="#noonan.REF.aoki.2005.1038">Aoki et al 2005</a>].</p><p><b>Noonan syndrome-like disorder with loose anagen hair</b> (OMIM <a href="http://omim.org/entry/607721" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607721</a>). Germline pathogenic variants in <i>SHOC2</i> usually lead to a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of Noonan-like features; a small proportion of those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> have the classic Noonan syndrome phenotype [Kerr, personal experience]. The recurrent pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>SHOC2</i> variant, 4A&#x0003e;G, has been found in a subgroup with features of NS but also growth hormone deficiency; distinctive hyperactive behavior that improves with age in most; hair anomalies including easily pluckable, sparse, thin slow-growing hair (loose anagen hair); darkly pigmented skin with eczema or ichthyosis; hypernasal voice; and an overrepresentation of mitral valve dysplasia and septal defects in comparison with classic NS [<a class="bk_pop" href="#noonan.REF.cordeddu.2009.1022">Cordeddu et al 2009</a>]. Sequence analysis of all exons detects a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in about 5% of individuals with Noonan syndrome. Most have the classic loose anagen hair [<a class="bk_pop" href="#noonan.REF.cordeddu.2009.1022">Cordeddu et al 2009</a>].</p><p><b>Noonan syndrome-like disorder with or without JMML</b> (OMIM <a href="http://omim.org/entry/613563" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613563</a>). Germline pathogenic variants in <i>CBL</i> cause a variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> characterized by a relatively high frequency of neurologic features, predisposition to juvenile myelomonocytic leukemia, and low prevalence of cardiac defects, reduced growth, and cryptorchidism [<a class="bk_pop" href="#noonan.REF.martinelli.2010.250">Martinelli et al 2010</a>, <a class="bk_pop" href="#noonan.REF.niemeyer.2010.794">Niemeyer et al 2010</a>, <a class="bk_pop" href="#noonan.REF.martinelli.2015.787">Martinelli et al 2015</a>].</p><p>Due to the significant phenotypic overlap with classic NS, most RASopathy diagnostic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> panels include testing for the common <i>SHOC2</i> variant and <i>CBL</i> gene sequencing.</p><p><b>Other.</b> NS should be distinguished from other syndromes/conditions with developmental delay, short stature, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defects, and distinctive facies, especially the following:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/williams/">Williams syndrome</a></div></li><li class="half_rhythm"><div>Aarskog syndrome (OMIM <a href="http://omim.org/entry/100050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">100050</a>)</div></li><li class="half_rhythm"><div>In utero exposure to alcohol or primidone</div></li></ul><p><a href="/books/n/gene/nf1/"><b>Neurofibromatosis 1</b></a>
<b>(NF1)</b> shares some features with NS, including short stature, learning difficulties, and caf&#x000e9; au lait patches. Infrequently, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals also have a NS-like facial appearance. This could be caused by chance concurrence of NS and NF1 [<a class="bk_pop" href="#noonan.REF.colley.1996.59">Colley et al 1996</a>, <a class="bk_pop" href="#noonan.REF.bertola.2005.242">Bertola et al 2005</a>]. However, most often it appears to be a NS-like facial appearance in an individual with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>NF1</i>, sometimes in the presence of a variant NF1 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#noonan.REF.stevenson.2006.246">Stevenson et al 2006</a>, <a class="bk_pop" href="#noonan.REF.nystr_m.2009.524">Nystr&#x000f6;m et al 2009</a>].</p></div><div id="noonan.Management"><h2 id="_noonan_Management_">Management</h2><div id="noonan.Evaluations_Following_Initial_Dia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Noonan syndrome (NS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Complete physical and neurologic examination</div></li><li class="half_rhythm"><div>Plotting of growth parameters on NS growth charts</div></li><li class="half_rhythm"><div>Cardiac evaluation with echocardiography and electrocardiography</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Hearing evaluation</div></li><li class="half_rhythm"><div>Coagulation screen to include CBC with differential, PT/PTT (repeat after 12 months if age &#x0003c;12 months at the time of first screening [<a class="bk_pop" href="#noonan.REF.romano.2010.746">Romano et al 2010</a>, <a class="bk_pop" href="#noonan.REF.roberts.2013.333">Roberts et al 2013</a>]</div></li><li class="half_rhythm"><div>Renal ultrasound examination; urinalysis if the urinary tract is anomalous</div></li><li class="half_rhythm"><div>Clinical and radiographic assessment of spine and rib cage</div></li><li class="half_rhythm"><div>Brain and cervical spine MRI if neurologic symptoms are present</div></li><li class="half_rhythm"><div>Multidisciplinary developmental evaluation</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="noonan.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment of the complications of Noonan syndrome is generally standard and does not differ from treatment in the general population.</p><p>Management guidelines have been developed by Dyscerne, a European consortium [<a class="bk_pop" href="#noonan.REF1">Noonan Syndrome Guideline Development Group 2010</a>] (<a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>); a separate set has been published by an American consortium working with the Noonan Syndrome Support Group [<a class="bk_pop" href="#noonan.REF.romano.2010.746">Romano et al 2010</a>] and in the <i>Lancet</i> [<a class="bk_pop" href="#noonan.REF.roberts.2013.333">Roberts et al 2013</a>].</p><p>Treatment of cardiovascular anomalies is generally the same as in the general population. Pulmonary valve stenosis treated with percutaneous balloon pulmonary valvuloplasty has a higher reintervention rate vs pulmonary valve stenosis without NS [<a class="bk_pop" href="#noonan.REF.prendiville.2014.629">Prendiville et al 2014</a>]. There is substantial early mortality associated with hypertrophic cardiomyopathy; infants presenting before age six months in congestive heart failure have the worst prognosis (2-year survival of 30%) [<a class="bk_pop" href="#noonan.REF.hickey.2011.41">Hickey et al 2011</a>, <a class="bk_pop" href="#noonan.REF.wilkinson.2012.442">Wilkinson et al 2012</a>].</p><p>Developmental disabilities should be addressed by early intervention programs and individualized education strategies.</p><p>The bleeding diathesis in Noonan syndrome can have a variety of causes. Specific treatment for serious bleeding may be guided by knowledge of a factor deficiency or platelet aggregation anomaly. Factor VIIa has been successfully used to control bleeding caused by hemophilia, von Willebrand disease, thrombocytopenia, and thrombasthenia. It has also been used in an infant with Noonan syndrome whose platelet count and prothrombin and partial thromboplastin times were normal, to control severe postoperative blood loss resulting from gastritis [<a class="bk_pop" href="#noonan.REF.tofil.2005.352">Tofil et al 2005</a>].</p><p>Studies of growth hormone (GH) treatment have been published from the UK, Japan [<a class="bk_pop" href="#noonan.REF.ogawa.2004.61">Ogawa et al 2004</a>], the Netherlands [<a class="bk_pop" href="#noonan.REF.noordam.2007.24">Noordam 2007</a>, <a class="bk_pop" href="#noonan.REF.noordam.2008.203">Noordam et al 2008</a>], Sweden [<a class="bk_pop" href="#noonan.REF.osio.2005.1232">Osio et al 2005</a>], and the United States [<a class="bk_pop" href="#noonan.REF.romano.2009.2338">Romano et al 2009</a>].</p><ul><li class="half_rhythm"><div>The rationale for GH treatment of individuals with Noonan syndrome includes:</div><ul><li class="half_rhythm"><div>Significant short stature compared with normal peers;</div></li><li class="half_rhythm"><div>Possible impairment of the GH-insulin-like-growth-factor type I (GH-IGF-I) axis; and</div></li><li class="half_rhythm"><div>Documented response to GH treatment in studies.</div></li></ul></li><li class="half_rhythm"><div>In Europe, GH treatment is the standard of care for children with abnormalities of the GH-IGF-I axis and could be used when GH physiology is normal.</div></li><li class="half_rhythm"><div>No standard dose has been established; no correlation between dosage used and final height is apparent.</div></li><li class="half_rhythm"><div>Short stature due to Noonan syndrome is an FDA-approved indication for growth hormone treatment.</div></li></ul><p>Short- and long-term studies have demonstrated a consistent and significant increase in height velocity in children with Noonan syndrome who have been treated [<a class="bk_pop" href="#noonan.REF.osio.2005.1232">Osio et al 2005</a>, <a class="bk_pop" href="#noonan.REF.noordam.2008.203">Noordam et al 2008</a>, <a class="bk_pop" href="#noonan.REF.romano.2009.2338">Romano et al 2009</a>].</p><p>The increase in height SD varies from 0.6 to 1.8 SD and may depend on age at start of treatment, duration of study, age at onset of puberty, and/or GH sensitivity [<a class="bk_pop" href="#noonan.REF.osio.2005.1232">Osio et al 2005</a>, <a class="bk_pop" href="#noonan.REF.noordam.2008.203">Noordam et al 2008</a>, <a class="bk_pop" href="#noonan.REF.dahlgren.2009.46">Dahlgren 2009</a>].</p><p>Subsequent studies have shown that children with prepubertal NS growth hormone deficiency have been shown to increase their growth rate with growth hormone therapy at a rate equivalent to girls with Turner syndrome but at a lower rate than that seen in <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> growth hormone deficiency [<a class="bk_pop" href="#noonan.REF.lee.2015.17">Lee et al 2015</a>, <a class="bk_pop" href="#noonan.REF.zavras.2015.71">Zavras et al 2015</a>].</p></div><div id="noonan.Surveillance"><h3>Surveillance</h3><p>If anomalies are found in any system (see <a href="#noonan.Evaluations_Following_Initial_Dia">Evaluations Following Initial Diagnosis</a>), periodic follow up should be planned and lifelong monitoring may be necessary; for example, periodic eye examination if a refraction error or strabismus is found, urinalysis if there are structural abnormalities of the collecting system. Despite the apparent increased incidence of hematologic and solid tumor malignancies, no surveillance strategies have been evaluated or recommended.</p></div><div id="noonan.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Aspirin therapy should be avoided because it may exacerbate a bleeding diathesis.</p></div><div id="noonan.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#noonan.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="noonan.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="noonan.Genetic_Counseling"><h2 id="_noonan_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="noonan.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Noonan syndrome (NS) caused by pathogenic variants in <i>BRAF</i>, <i>KRAS</i>, <i>MAP2K1</i>, <i>NRAS</i>, <i>PTPN11</i>, <i>RAF1</i>, <i>RIT1</i>, or <i>SOS1</i> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p>NS caused by pathogenic variants in <i>LZTR1</i> can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="noonan.Autosomal_Domiant_Inheritance__Ri"><h3>Autosomal Domiant Inheritance &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">30%-75% of individuals diagnosed with NS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div class="half_rhythm">A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with NS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in an NS-related <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</div><div class="half_rhythm">In <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., those with no known family history), paternal origin of the <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been found universally to date [<a class="bk_pop" href="#noonan.REF.tartaglia.2004a.492">Tartaglia et al 2004a</a>]. In this cohort, advanced paternal age was observed along with a significant sex-ratio bias favoring transmission to males, a finding that is thus far unexplained.</div></li><li class="half_rhythm"><div class="half_rhythm">It is appropriate to evaluate both parents, including a thorough physical examination with particular attention to the features of NS; echo- and electrocardiography; coagulation screening; and review of photographs of the face at all ages, searching for characteristic features of NS. Molecular genetic testing of parents is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is known.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected and the NS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to the sibs of a proband appears to be low (&#x0003c;1%) but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (germline mosaicism for the <i>PTPN11</i> c.922A&#x0003e;G pathogenic variant is reviewed by <a class="bk_pop" href="#noonan.REF.yoon.2013.917">Yoon et al [2013]</a>; click <a href="/books/NBK1124/bin/noonan-var_distribution.pdf">here</a> for text).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with NS has a 50% chance of inheriting the NS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members may be at risk.</p></div><div id="noonan.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance</h3><div id="noonan.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>LZTR1</i>.</div></li><li class="half_rhythm"><div>Heterozygotes may be asymptomatic [<a class="bk_pop" href="#noonan.REF.johnston.2018.1175">Johnston et al 2018</a>] or may have mild features of NS.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of having an <i>LZTR1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (which can be associated with mild NS features), and a 25% chance of being unaffected and not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>.</div></li><li class="half_rhythm"><div>Heterozygotes may be asymptomatic or may have mild features of NS.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with NS are obligate heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>LZTR1</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>LZTR1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="noonan.Heterozygote_Detection"><h4>Heterozygote Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the <i>LZTR1</i> pathogenic variants in the family.</p></div></div><div id="noonan.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NS has an NS-related pathogenic variant or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations such as <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="noonan.Prenatal_Testing_and_Preimplantat"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancy</b></p><ul><li class="half_rhythm"><div><b>Molecular genetic testing.</b> Once the NS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for NS are possible.</div></li><li class="half_rhythm"><div><b>Ultrasound examination.</b> For pregnancies at 50% risk, high-resolution ultrasound examination is also possible. Prenatal features are nonspecific but may include polyhydramnios, hydronephrosis, pleural effusion, edema, cardiac defects, distended jugular lymphatic sacs, cystic hygroma, and increased nuchal translucency [<a class="bk_pop" href="#noonan.REF.nisbet.1999.642">Nisbet et al 1999</a>, <a class="bk_pop" href="#noonan.REF.schl_ter.2005.574">Schl&#x000fc;ter et al 2005</a>, <a class="bk_pop" href="#noonan.REF.houweling.2010.284">Houweling et al 2010</a>]. Cystic hygroma may be accompanied by scalp edema, polyhydramnios, pleural and pericardial effusions, ascites, and/or frank hydrops fetalis. The presence of these findings should suggest the diagnosis of NS. In addition, a search for a cardiac defect should be made, although <a class="bk_pop" href="#noonan.REF.menashe.2002.51">Menashe et al [2002]</a> has pointed out how infrequently such a defect will be detected prenatally. Among fetuses with normal chromosomes, the diagnosis of NS will be made in approximately 5%-15% of cases with nuchal edema detected in the first trimester [<a class="bk_pop" href="#noonan.REF.reynders.1997.101">Reynders et al 1997</a>, <a class="bk_pop" href="#noonan.REF.adekunle.1999.457">Adekunle et al 1999</a>, <a class="bk_pop" href="#noonan.REF.nisbet.1999.642">Nisbet et al 1999</a>, <a class="bk_pop" href="#noonan.REF.hiippala.2001.18">Hiippala et al 2001</a>, <a class="bk_pop" href="#noonan.REF.bakker.2014.355">Bakker et al 2014</a>] and 10% of second-trimester fetuses with a cystic hygroma [<a class="bk_pop" href="#noonan.REF.lee.2009.190">Lee et al 2009</a>]. Treatment of these complications is the same as that in the general population.</div></li></ul><p><b>Low-risk pregnancy.</b> Although the ultrasonographic findings described suggest the diagnosis of NS in high-risk pregnancies, they are nonspecific and may be associated with cardiovascular defects or other <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> and non-chromosome syndromes.</p></div></div><div id="noonan.Resources"><h2 id="_noonan_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Noonan%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Noonan syndrome</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=noonansyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Noonan syndrome</a></div></li><li class="half_rhythm"><div><b>Noonan Syndrome Foundation</b></div><div><b>Email:</b> info@teamnoonan.org</div><div><a href="http://www.teamnoonan.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.teamnoonan.org</a></div></li><li class="half_rhythm"><div><b>RASopathiesNet</b></div><div>244 Taos Road</div><div>Atlandena CA 91001</div><div><b>Phone:</b> 626-676-7694</div><div><b>Email:</b> lisa@rasopathies.org</div><div><a href="http://rasopathiesnet.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rasopathiesnet.org</a></div></li><li class="half_rhythm"><div><b>Human Growth Foundation (HGF)</b></div><div>997 Glen Cove Avenue</div><div>Suite 5</div><div>Glen Head NY 11545</div><div><b>Phone:</b> 800-451-6434 (toll-free)</div><div><b>Fax:</b> 516-671-4055</div><div><b>Email:</b> hgf1@hgfound.org</div><div><a href="http://www.hgfound.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hgfound.org</a></div></li><li class="half_rhythm"><div><b>MAGIC Foundation</b></div><div>4200 Cantera Drive #106</div><div>Warrenville IL 60555</div><div><b>Phone:</b> 800-362-4423 (Toll-free Parent Help Line); 630-836-8200</div><div><b>Fax:</b> 630-836-8181</div><div><b>Email:</b> contactus@magicfoundation.org</div><div><a href="http://www.magicfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.magicfoundation.org</a></div></li></ul></div><div id="noonan.Molecular_Genetics"><h2 id="_noonan_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="noonan.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Noonan Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/673" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BRAF</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=673" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q34</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P15056" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Serine/threonine-protein kinase B-raf</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF database</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRAF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRAF[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BRAF</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3845" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KRAS</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3845" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p12<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01116" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTPase KRas</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS database</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KRAS</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8216" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LZTR1</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8216" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q11<wbr style="display:inline-block"></wbr>​.21</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q8N653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Leucine-zipper-like transcriptional regulator 1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/LZTR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1 @ LOVD</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LZTR1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LZTR1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LZTR1</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5604" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MAP2K1</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5604" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q22<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q02750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dual specificity mitogen-activated protein kinase kinase 1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1 @ LOVD</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAP2K1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAP2K1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAP2K1</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4893" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>NRAS</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4893" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P01111" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTPase NRas</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/NRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS database</a><br /><a href="http://structure.bmc.lu.se/idbase/NRASbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRASbase: Mutation registry for Autoimmune lymphoproliferative syndrome type IV</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NRAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NRAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NRAS</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5781" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PTPN11</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5781" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q24<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q06124" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tyrosine-protein phosphatase non-receptor type 11</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/PTPN11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11 database</a><br /><a href="http://structure.bmc.lu.se/idbase/PTPN11base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11base: Database for pathogenic mutations in the SHP-2 SH2 domain</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PTPN11" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PTPN11[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PTPN11</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5894" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RAF1</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5894" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p25<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P04049" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF proto-oncogene serine/threonine-protein kinase</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAF1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAF1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RAF1</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6016" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RIT1</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6016" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q22</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92963" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GTP-binding protein Rit1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RIT1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RIT1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RIT1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RIT1</a></td></tr><tr><td headers="hd_b_noonan.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6654" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SOS1</i></a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6654" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q07889" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Son of sevenless homolog 1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SOS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1 database</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SOS1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1</a></td><td headers="hd_b_noonan.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SOS1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SOS1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="noonan.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="noonan.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Noonan Syndrome (<a href="/omim/163950,164757,164760,164790,176872,176876,182530,190070,600574,605275,609591,609942,610733,611553,613224,613706,615355,616564" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/163950" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">163950</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 1; NS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164757" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164757</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; BRAF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164760" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164760</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V-RAF-1 MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; RAF1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164790" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164790</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NRAS PROTOONCOGENE, GTPase; NRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176872" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176872</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1; MAP2K1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176876" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176876</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 11; PTPN11</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/182530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">182530</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOS RAS/RAC GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; SOS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/190070" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">190070</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRAS PROTOONCOGENE, GTPase; KRAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600574" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600574</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LEUCINE ZIPPER-LIKE TRANSCRIPTIONAL REGULATOR 1; LZTR1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605275" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605275</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 2; NS2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609591" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609591</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 1; RIT1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609942" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609942</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 3; NS3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/610733" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">610733</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 4; NS4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/611553" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">611553</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 5; NS5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613224" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613224</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 6; NS6</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613706" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613706</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 7; NS7</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615355" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615355</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 8; NS8</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/616564" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">616564</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NOONAN SYNDROME 10; NS10</td></tr></tbody></table></div></div><p><b><i>BRAF</i></b></p><p><b>Gene structure.</b>
<i>BRAF</i> encodes B-RAF, a member of the RAF family, which also includes C-RAF and A-RAF encoded by the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>ARAF</i>. <i>BRAF</i> spans approximately 190 kb and comprises 18 exons. For a detailed summary of gene and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Four variants have been associated with NS (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 p.Thr241Met and p.Thr241Arg, exon 13 p.Trp531Cys, and exon 15 p.Leu597Val); all showed slight increase in MEK phosphorylation in vitro [<a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al 2009</a>]. Two exon 6 variants (c.721A&#x0003e;C;p.Thr241Pro and c.735A&#x0003e;G;p.Leu245Phe) have been reported in Noonan syndrome with multiple lentigines [<a class="bk_pop" href="#noonan.REF.koudova.2009.337">Koudova et al 2009</a>, <a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al 2009</a>]. These variants are novel, never having been identified as somatic pathogenic variants in cancer. Two pathogenic variants were <i>de</i>
<i>novo</i> and one was <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>.</p><div id="noonan.T.braf_variants_discussed_in_this" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>BRAF</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.T.braf_variants_discussed_in_this/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.braf_variants_discussed_in_this_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequence</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.722C&#x0003e;T</td><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr241Met</td><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_004333.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004333<wbr style="display:inline-block"></wbr>​.4</a></td></tr><tr><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.722C&#x0003e;G</td><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr241Arg</td></tr><tr><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1593G&#x0003e;C</td><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp531Cys</td></tr><tr><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1789C&#x0003e;G</td><td headers="hd_h_noonan.T.braf_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu597Val</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein product of <i>BRAF</i> is B-RAF, a serine/threonine protein kinase that is one of the many direct downstream effectors of R-RAF. The RAF/MEK/ERK module of kinases is critically involved in cell proliferation, differentiation, motility, apoptosis, and senescence. B-RAF has only two known downstream effectors, mitogen-activated protein kinase 1 and 2 (also known as MEK1 and MEK2) [<a class="bk_pop" href="#noonan.REF.sithanandam.1990.1775">Sithanandam et al 1990</a>, <a class="bk_pop" href="#noonan.REF.solit.2006.358">Solit et al 2006</a>].</p><p>The three conserved regions (CR) in B-RAF:</p><ul><li class="half_rhythm"><div>CR1 (conserved region 1), containing the RAS-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and the cysteine-rich domain, both of which are required for recruitment of B-RAF to the cell membrane</div></li><li class="half_rhythm"><div>CR2, the smallest of the conserved regions</div></li><li class="half_rhythm"><div>CR3, the kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> containing the glycine-rich loop (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11) and the activation segment (exon 15) of the catalytic domain</div></li></ul><p>Exons 3-6 encode a RAS-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (RBD) and a cysteine-rich domain (CRD), while the kinase domain is encoded by exons 11-17.</p><p><i>BRAF</i> is ubiquitously expressed and encodes a protein of 766 amino acids. It is activated following GTP-bound RAS binding, and phosphorylates and activates the dual specificity mitogen-activated protein kinase kinases (MEK1 and MEK2).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> NS-associated variants are primarily observed in exons 6, 13, and 15 (vs CFC-associated <i>BRAF</i> variants: exons 6, 12, 15, and 16) [<a class="bk_pop" href="#noonan.REF.sarkozy.2009.695">Sarkozy et al 2009</a>]. The NS-related variants are different from the CFC-related variants, although why some variants are associated with a NS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and some a CFC phenotype is not understood.</p><p><b><i>KRAS</i></b></p><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> comprises four exons spanning 45 kb. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> produces two <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> (4a and 4b) that differ at the C terminus. In 98% of transcripts, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4a is spliced out; and only exon 4b is available for translation into protein. The effector or switch domains are part of exons 1 and 2, while binding to guanine nucleotide exchange factors occurs in exon 3. For a detailed summary of gene and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The association between abnormal K-RAS and Noonan syndrome is the first evidence of a role in embryonic development. These <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> pathogenic variants confer biochemical and cellular phenotypes similar to Noonan syndrome-associated SHP-2 pathogenic variants [<a class="bk_pop" href="#noonan.REF.kratz.2007.227">Kratz et al 2007</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> RAS proteins regulate cell fates by cycling between active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound conformations. They are key regulators of the RAS-RAF-MEK-ERK pathway, which is important for proliferation, growth, and death of cells.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The abnormal K-RAS protein induces hypersensitivity of primary hematopoietic progenitor cells to growth factors and deregulates signal transduction in a cell lineage-specific manner [<a class="bk_pop" href="#noonan.REF.kratz.2007.227">Kratz et al 2007</a>]. Strong <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> <i>KRAS</i> pathogenic variants may be incompatible with life.</p><p><b><i>LZTR1</i></b></p><p><b>Gene structure.</b>
<i>LZTR1</i> (leucine-zipper-like transcription regulator 1) encodes a member of the BTB-kelch superfamily.</p><p>For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> It has been hypothesized that either the type of variant (<a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> vs <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> and <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants) or location (<a class="def" href="/books/n/gene/glossary/def-item/hot-spot/">hot spot</a> region between codons 119 and 287 vs throughout the rest of the protein) explains dominant vs recessive variants, respectively. Recent work demonstrates that recessive variants typically influence protein synthesis/stability or subcellular localization while dominant variants enhance EGF-dependent ERK1/2 phosphorylation [<a class="bk_pop" href="#noonan.REF.motta.2019.1007">Motta et al 2019</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene product localizes exclusively to the Golgi network, where it may help stabilize the Golgi complex. LZTR1 binds the RAF1-SHOC2-PPP1CB complex.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Ubiquitome analysis showed that loss of LZTR1 abrogated Ras ubiquitination at lysine-170. LZTR1-mediated ubiquitination inhibited RAS signaling by attenuating its association with the membrane [<a class="bk_pop" href="#noonan.REF.steklov.2018.1177">Steklov et al 2018</a>]. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS [<a class="bk_pop" href="#noonan.REF.bigenzahn.2018.1171">Bigenzahn et al 2018</a>].</p><p><b><i>MAP2K1</i></b></p><p><b>Gene structure.</b> MEK exists as a multigene family. <i>MAP2K1</i> spans approximately 104 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>MAP2K1</i> cause Noonan syndrome in fewer than 2% of clinically diagnosed individuals.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>MAP2K1</i> encodes a threonine/tyrosine kinase with the ability to activate ERK1 and ERK2. The normal protein encoded by <i>MAP2K1</i> is dual-specificity mitogen-activated protein kinase kinase 1 (MEK1). Although the MEK1 and related MEK2 (encoded by <i>MAP2K2</i>) proteins have approximately 85% amino acid identity, they do not serve redundant purposes as determined in mouse development.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Three individuals with NS had a novel <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 of <i>MAP2K1</i>. These pathogenic variants were found in exons already identified as mutational hot spots in cardiofaciocutaneous syndrome [<a class="bk_pop" href="#noonan.REF.nava.2007.763">Nava et al 2007</a>].</p><p><b><i>NRAS</i></b></p><p><b>Gene structure.</b>
<i>NRAS</i> comprises seven exons. There are two main <i>NRAS</i> transcripts of 4.3 kb and 2 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The four pathogenic variants reported in association with NS are p.Ile24Asn, p.Pro34Leu, p.Thr50Ile, and p.Gly60Glu [<a class="bk_pop" href="#noonan.REF.cirstea.2010.27">Cirstea et al 2010</a>, <a class="bk_pop" href="#noonan.REF.runtuwene.2011.393">Runtuwene et al 2011</a>, <a class="bk_pop" href="#noonan.REF.denayer.2012.34">Denayer et al 2012</a>]. The p.Thr50Ile substitution is located within a conserved residue located in the beta-2-beta-3 loop connecting the two switch regions. In vitro functional expression studies showed that the mutated protein resulted in enhanced downstream phosphorylation in the presence of serum. Protein modeling suggests that p.Thr50 interacts with the polar heads of membrane phospholipids and is an integral part of a region that controls RAS membrane orientation. In vitro functional expression studies showed that the p.Gly60Glu variant resulted in enhanced downstream phosphorylation in the presence of serum and that mutated protein accumulated constitutively in the active GTP-bound form [<a class="bk_pop" href="#noonan.REF.cirstea.2010.27">Cirstea et al 2010</a>]. Protein variant p.Ile24Asn is classified as pathogenic because of its occurrence in a highly conserved residue and <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> origin. It was shown to be a mildly activating <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in enhanced downstream signaling and causing developmental defects, including cell migration defects during gastrulation in zebrafish embryos [<a class="bk_pop" href="#noonan.REF.runtuwene.2011.393">Runtuwene et al 2011</a>]. Pro34 is located in the switch I region of RAS, and another pathogenic variant in this residue (p.Pro34Arg) has been shown to accumulate in the GTP-bound conformation and to strongly activate the MAPK pathway [<a class="bk_pop" href="#noonan.REF.schubbert.2006.331">Schubbert et al 2006</a>].</p><div id="noonan.T.nras_variants_discussed_in_this" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>NRAS</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.T.nras_variants_discussed_in_this/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.nras_variants_discussed_in_this_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.71T&#x0003e;A</td><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile24Asn</td><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_002524.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002524<wbr style="display:inline-block"></wbr>​.4</a></td></tr><tr><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.101C&#x0003e;T</td><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro34Leu</td></tr><tr><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.149C&#x0003e;T</td><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr50Ile</td></tr><tr><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.179G&#x0003e;A</td><td headers="hd_h_noonan.T.nras_variants_discussed_in_this_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly60Glu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> RAS proteins act as molecular switches through cycling between inactive GDP-bound and active GTP-bound states. In its active form, RAS can interact productively with more than 20 effectors including Raf, phosphatidylinositol-3-kinase, and RAL-GDP dissociation simulator (GDS). This activates the RAF-MEK-MAPK cascade, which promotes cell proliferation, differentiation, or survival.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Expression of the NS-associated <i>NRAS</i> substitutions p.Thr50Ile or p.Gly60Glu in cellular models resulted in enhanced phosphorylation of MEK and ERK in the presence of serum or after epidermal growth factor (EGF) stimulation [<a class="bk_pop" href="#noonan.REF.cirstea.2010.27">Cirstea et al 2010</a>]. Similar to <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>KRAS</i> pathogenic variants causing Noonan syndrome and cardiofaciocutaneous syndrome, germline <i>NRAS</i> alterations do not affect residues commonly altered in human cancers and appear to be less activating in dysregulating intracellular signaling in vitro compared with cancer-associated somatic pathogenic variants (see <a href="#noonan.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</a>).</p><p><b><i>PTPN11</i></b></p><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> comprises 15 exons. For a detailed summary of gene and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b>
<a class="bk_pop" href="#noonan.REF.tartaglia.2001.465">Tartaglia et al [2001]</a> identified a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PTPN11</i> as causative of Noonan syndrome. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>PTPN11</i> were identified in 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals examined; 95% of these pathogenic variants alter residues at or close to the SH2-PTP interacting surfaces, which are involved in switching between active and inactive conformations of the protein and cause catalytic activation and gain of function. Five percent of the pathogenic variants alter sensitivity to activation from binding partners. One <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, <a class="figpopup" href="/books/NBK1124/table/noonan.T.selected_ptpn11_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="fignoonanTselectedptpn11pathogenicvari" rid-ob="figobnoonanTselectedptpn11pathogenicvari">p.Gly60del</a>, has been described [<a class="bk_pop" href="#noonan.REF.yoshida.2004a.3359">Yoshida et al 2004a</a>]. <i>PTPN11</i> duplications and deletions, although rare, have most often been associated with a "Noonan-like" <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#noonan.REF.shchelochkov.2008.1042">Shchelochkov et al 2008</a>, <a class="bk_pop" href="#noonan.REF.graham.2009.2122">Graham et al 2009</a>, <a class="bk_pop" href="#noonan.REF.luo.2012.1918">Luo et al 2012</a>, <a class="bk_pop" href="#noonan.REF.chen.2014a.28">Chen et al 2014a</a>]. Given the known <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism of disease (hyperactivation of the pathway), it is debatable how <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletion or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> could truly cause Noonan syndrome [<a class="bk_pop" href="#noonan.REF.lissewski.2015.2685">Lissewski et al 2015</a>].</p><p>See <a class="figpopup" href="/books/NBK1124/table/noonan.T.selected_ptpn11_pathogenic_vari/?report=objectonly" target="object" rid-figpopup="fignoonanTselectedptpn11pathogenicvari" rid-ob="figobnoonanTselectedptpn11pathogenicvari">Table 4</a>.</p><div id="noonan.T.selected_ptpn11_pathogenic_vari" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>PTPN11</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1124/table/noonan.T.selected_ptpn11_pathogenic_vari/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__noonan.T.selected_ptpn11_pathogenic_vari_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.922A&#x0003e;G</td><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn308Asp</td><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/33356176?report=genbank" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002834<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=33356177" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002825<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.179_181delGTG</td><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly60del</td></tr><tr><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.181_183delGAT</td><td headers="hd_h_noonan.T.selected_ptpn11_pathogenic_vari_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp61del</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>PTPN11</i> encodes tyrosine-protein phosphatase non-receptor type 11 (SHP-2), a widely expressed extracellular protein that has two tandemly arranged SRC-2 homology 2 (SH2) domains at the N terminus (N-SH2 and C-SH2), a single catalytic protein tyrosine phosphatase (PTP) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, and a carboxy tail with two TP sites and a proline-rich stretch. The SH2-PTP interaction maintains the protein in an inactive state. The protein is a key molecule in the cellular response to growth factors, hormones, cytokines, and cell adhesion molecules. It is required in several intracellular signal transduction pathways that control diverse developmental processes (including cardiac semilunar valvulogenesis and blood cell progenitor commitment and differentiation) and has a role in modulating cellular proliferation, differentiation, migration, and apoptosis [<a class="bk_pop" href="#noonan.REF.tartaglia.2002.1555">Tartaglia et al 2002</a>, <a class="bk_pop" href="#noonan.REF.fragale.2004.267">Fragale et al 2004</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Activation of tyrosine-protein phosphatase non-receptor type II stimulates epidermal growth factor-mediated RAS/ERK/MAPK activation, increasing cell proliferation [<a class="bk_pop" href="#noonan.REF.tartaglia.2002.1555">Tartaglia et al 2002</a>, <a class="bk_pop" href="#noonan.REF.fragale.2004.267">Fragale et al 2004</a>].</p><p><b><i>RAF1</i></b></p><p><b>Gene structure.</b>
<i>RAF1</i> comprises 17 exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The consensus 14-3-3 recognition site includes amino acid residues p.Arg256, p.Ser257, p.Ser259, and p.Pro261 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7. Many of the pathogenic variants identified in Noonan syndrome cluster in this CR2 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, interfere with 14-3-3 binding, and cause greater kinase activity than wild type protein, both basally and after EGF stimulation [<a class="bk_pop" href="#noonan.REF.pandit.2007.1007">Pandit et al 2007</a>]. Other pathogenic variants reside in the RAF activation segment in CR3 and show reduced or absent kinase activity. However, they still result in constitutive ERK activation.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>RAF1</i> is ubiquitously expressed and encodes a protein of 648 amino acids with three domains. It has three conserved regions (CR). CR1 (exons 2-5) encode a RAS-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (RBD) and a cysteine-rich domain (CRD). CR2 lies in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7, while CR3, which spans exons 10-17, encodes an activation segment. The gene is highly regulated with numerous serine and threonine residues that can be phosphorylated, resulting in activation or inactivation. The p.Ser259 residue in CR2 is particularly important [<a class="bk_pop" href="#noonan.REF.pandit.2007.1007">Pandit et al 2007</a>]. In the inactive state, the N terminus of <i>RAF1</i> interacts with and inactivates the kinase domain at the C terminus. This conformation is stabilized by 14-3-3 protein dimers that bind to phosphorylated p.Ser259 and p.Ser261. Dephosphorylation of p.Ser259 facilitates binding of <i>RAF1</i> to RAS-GTP and propagation of the signal through the RAS-MAPK cascade via <i>RAF1</i>
<i>MEK</i> kinase activity [<a class="bk_pop" href="#noonan.REF.pandit.2007.1007">Pandit et al 2007</a>]. CR1 and CR2 both have negative regulatory function, removal of which results in oncogenic activity. The kinase domain, CR3, also associates with 14-3-3.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Noonan syndrome-associated <i>RAF1</i> pathogenic variants increase and prolong RAS activation and downstream signaling through enhanced RAS-GEF activity and reduced 14-3-3 binding and autoinhibition.</p><p><b><i>RIT1</i></b></p><p><b>Gene structure.</b> RIT belongs to the RAS subfamily of small GTPases. It is located at 1q22 and consists of six exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are estimated to cause approximately 5% of NS. The majority of pathogenic variants reported in NS cluster within the switch II region that corresponds to RAS [<a class="bk_pop" href="#noonan.REF.aoki.2016.33">Aoki et al 2016</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The RIT1 protein has a 50% sequence commonality with RAS but lacks the carboxyl-terminal CAAX motif found in several other RAS-like proteins [<a class="bk_pop" href="#noonan.REF.lee.1996.6784">Lee et al 1996</a>]. The encoded protein is involved in regulating p38 MAPK-dependent signaling cascades related to cellular stress. This protein also cooperates with nerve growth factor to promote neuronal development and regeneration [<a class="bk_pop" href="#noonan.REF.wes.1996.5839">Wes et al 1996</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Gain-of-function variants result in increased MEK-ERK signaling [<a class="bk_pop" href="#noonan.REF.aoki.2013.173">Aoki et al 2013</a>].</p><p><b><i>SOS1</i></b></p><p><b>Gene structure.</b>
<i>SOS1</i> comprises 23 exons and encodes a 150-kd multidomain protein. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1124/#noonan.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Noonan syndrome-associated <i>SOS1</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are hypermorphic; that is, they increase signaling through the RAS-MAPK pathway [<a class="bk_pop" href="#noonan.REF.roberts.2007.70">Roberts et al 2007</a>]. The vast majority are located in highly conserved sites. They cluster at codons encoding residues implicated in the maintenance of <i>SOS1</i> in its autoinhibited form. One such cluster is found in the codons encoding the PH <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and may disrupt the autoinhibited conformation by destabilizing the conformation of the DH domain. Another cluster resides in codons encoding the helical linker between the DH and REM domains. A third cluster affects codons of residues that mediate the interaction between the DH and REM domains.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> SOS1 (son of sevenless homolog 1) protein comprises a RAS-GEF (guanine nucleotide exchange factor) <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, a conserved histone-like fold, Dbl homology (DH) and plekstrin homology (PH) domains, a helical linker, a RAS exchange motif (REM), and a proline-rich region. The Dbl homology domain may act as a guanine nucleotide exchange factor (GEF) for the RAC family small G proteins (RAC-GEF). <i>SOS1</i> has two RAS-binding sites: an effector site in the Cdc25 domain and an allosteric site formed by the REM and Cdc25 domains. RAS binding to the allosteric site enhances RAS-GEF activity. The DH-PH module controls RAS binding at this site and likely acts as an intramolecular inhibitor of RAS-GEF activity. The entire N terminus functions as an integrated unit to inhibit the REM-Cdc25 domain.</p><p>SOS1 is a RAS-specific guanine nucleotide exchange factor (GEF). The protein is autoinhibited owing to complex regulatory intra- and intermolecular interactions. After receptor tyrosine kinase (RTK) stimulation, SOS1 is recruited to the plasma membrane, where it acquires a catalytically active conformation [<a class="bk_pop" href="#noonan.REF.soisson.1998.259">Soisson et al 1998</a>]. It then, in turn, catalyzes activation of the RAS-MAPK pathway by conversion of RAS-GDP to RAS-GTP.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Noonan syndrome-associated <i>SOS1</i> pathogenic variants abrogate autoinhibition, increasing and prolonging RAS activation and downstream signaling through enhanced RAS-GEF activity [<a class="bk_pop" href="#noonan.REF.roberts.2007.70">Roberts et al 2007</a>, <a class="bk_pop" href="#noonan.REF.tartaglia.2007.75">Tartaglia et al 2007</a>].</p><div id="noonan.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p>Sporadic tumors (including leukemia and solid tumors) occurring as single tumors in the absence of any other findings of Noonan syndrome may harbor somatic nucleotide variants in <i>PTPN11, KRAS</i>, <i>LZTR1</i>, <i>NRAS</i>, <i>BRAF</i>, <i>or MAP2K1</i> that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>; thus, predisposition to these tumors is not heritable. See <a href="http://cancer.sanger.ac.uk/cosmic" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Catalogue of Somatic Mutations in Cancer</a>.</p><ul><li class="half_rhythm"><div class="half_rhythm">Leukemia and solid tumors. Juvenile myelomonocytic leukemia (JMML) accounts for one third of myelodysplastic syndrome (MDS) and about 2% of leukemia. Pathogenic variants in NRAS, KRAS, and NF1 have been shown to deregulate the RAS-MAPK pathway leading to JMML in about 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Somatic pathogenic variants in exons 3 and 13 of PTPN11 have been demonstrated in 34% individuals with JMML in one cohort [<a class="bk_pop" href="#noonan.REF.tartaglia.2003b.148">Tartaglia et al 2003b</a>, <a class="bk_pop" href="#noonan.REF.tartaglia.2004b.307">Tartaglia et al 2004b</a>, <a class="bk_pop" href="#noonan.REF.hasle.2009.8">Hasle 2009</a>].</div><div class="half_rhythm">Pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 were also found in 19% of children with MDS with an excess of blast cells, which often evolves into acute myeloid leukemia (AML) and is associated with poor prognosis. Nonsyndromic AML, especially the monocyte subtype FAB-MD, has been shown to be caused by <i>PTPN11</i> pathogenic variants. All of these pathogenic variants cause gain of function in tyrosine-protein phosphatase non-receptor type II (SHP-2), likely leading to an early initiating lesion in JMML oncogenesis with increased cell proliferation attributable, in part, to prolonged activation of the RAS-MAPK pathway.</div><div class="half_rhythm">The spectrum of leukemogenesis associated with <i>PTPN11</i> pathogenic variants has been extended to include childhood acute lymphoblastic leukemia (ALL). Pathogenic variants were observed in 8% of individuals with B-cell precursor ALL, but not among children with T-lineage ALL [<a class="bk_pop" href="#noonan.REF.tartaglia.2004b.307">Tartaglia et al 2004b</a>]. Additionally, <a class="bk_pop" href="#noonan.REF.bentiresalj.2004.8816">Bentires-Alj et al [2004]</a> have described SHP-2-activating <i>PTPN11</i> pathogenic variants in solid tumors including breast, lung, and gastric neoplasms and neuroblastoma.</div></li><li class="half_rhythm"><div class="half_rhythm">Somatic <i>RAF1</i> nucleotide variants have only rarely been found in cancer; most of these cancer-causing variants do not cluster in the regions that are <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> mutational hot spots in Noonan syndorme.</div></li><li class="half_rhythm"><div class="half_rhythm"><i>NRAS</i> variants are commonly observed in somatic cancer; they occur in different regions than <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>NRAS</i> variants that cause Noonan syndrome.</div></li><li class="half_rhythm"><div class="half_rhythm"><i>MAP2K1</i> somatic variants have been reported in ovarian cancer [<a class="bk_pop" href="#noonan.REF.estep.2007.e1279">Estep et al 2007</a>] and lung cancer [<a class="bk_pop" href="#noonan.REF.marks.2008.5524">Marks et al 2008</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Somatic <i>SOS1</i> pathogenic variants have not been found in cancer.</div></li><li class="half_rhythm"><div class="half_rhythm">Recent studies have identified somatic <i>RIT1</i> pathogenic variants in lung adenocarcinoma, and myeloproliferative or mixed myelodysplastic/myeloproliferative neoplasms [<a class="bk_pop" href="#noonan.REF.berger.2014.4418">Berger et al 2014</a>, <a class="bk_pop" href="#noonan.REF.cancer_genome_atlas_research_network.2014.543">Cancer Genome Atlas Research Network 2014</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">The somatic p.Gly248Arg <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>LZTR1</i> has been identified in melanoma, glioblastoma, and colorectal cancers (<a href="https://cancer.sanger.ac.uk/cosmic" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COSMIC</a> database).</div></li></ul></div></div><div id="noonan.References"><h2 id="_noonan_References_">References</h2><div id="noonan.Published_Guidelines__Consensus_S"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="noonan.REF1">Noonan Syndrome Guideline Development Group. Management of Noonan syndrome &#x02013; a clinical guideline (pdf). University of Manchester: DYSCERNE. Available <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 8-1-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.roberts.2013.333">Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>:333–42.</span> [<a href="/pmc/articles/PMC4267483/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4267483</span></a>] [<a href="/pubmed/23312968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23312968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.romano.2010.746">Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. <span><span class="ref-journal">Pediatrics. </span>2010;<span class="ref-vol">126</span>:746–59.</span> [<a href="/pubmed/20876176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20876176</span></a>]</div></li></ul></div><div id="noonan.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.adekunle.1999.457">Adekunle O, Gopee A, el-Sayed M, Thilaganathan B. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. <span><span class="ref-journal">Br J Radiol. </span>1999;<span class="ref-vol">72</span>:457–60.</span> [<a href="/pubmed/10505009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10505009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.allanson.2010.1960">Allanson JE, Bohring A, D&#x000f6;rr HG, Dufke A, Gillessen-Kaesbach G, Horn D, K&#x000f6;nig R, Kratz CP, Kutsche K, Pauli S, Raskin S, Rauch A, Turner A, Wieczorek D, Zenker M. The face of Noonan syndrome: does phenotype predict genotype. <span><span class="ref-journal">Am J Med Genet. </span>2010;<span class="ref-vol">152A</span>:1960–6.</span> [<a href="/pmc/articles/PMC3115585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3115585</span></a>] [<a href="/pubmed/20602484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20602484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.allanson.1991.752">Allanson JE, Upadhyaya M, Watson GH, Partington M, MacKenzie A, Lahey D, MacLeod H, Sarfarazi M, Broadhead W, Harper PS, Huson SM. Watson syndrome: is it a subtype of type 1 neurofibromatosis? <span><span class="ref-journal">J Med Genet. </span>1991;<span class="ref-vol">28</span>:752–6.</span> [<a href="/pmc/articles/PMC1017110/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1017110</span></a>] [<a href="/pubmed/1770531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1770531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.armour.2008.249">Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. <span><span class="ref-journal">J Med Genet. </span>2008;<span class="ref-vol">45</span>:249–54.</span> [<a href="/pubmed/18039946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18039946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.aoki.2013.173">Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, Hoshika T, Barnett C, Ohashi H, Kawame H, Hasegawa T, Okutani T, Nagashima T, Hasegawa S, Funayama R, Nagashima T, Nakayama K, Inoue S, Watanabe Y, Ogura T, Matsubara Y. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">93</span>:173–80.</span> [<a href="/pmc/articles/PMC3710767/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3710767</span></a>] [<a href="/pubmed/23791108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23791108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.aoki.2016.33">Aoki Y, Niihori T, Inoue SI, Matsubara Y. Recent advances in RASopathies. <span><span class="ref-journal">J Hum Genet. </span>2016;<span class="ref-vol">61</span>:33–9.</span> [<a href="/pubmed/26446362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26446362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.aoki.2005.1038">Aoki Y, Niihori H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. Germline mutations in HRAS proto-oncogene cause Costello syndrome. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:1038–40.</span> [<a href="/pubmed/16170316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16170316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bakker.2014.355">Bakker M, Pajkrt E, Bilardo CM. Increased nuchal translucency with normal karyotype and anomaly scan: what next? <span><span class="ref-journal">Best Pract Res Clin Obstet Gynaecol. </span>2014;<span class="ref-vol">28</span>:355–66.</span> [<a href="/pubmed/24332983" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24332983</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.beneteau.2009.1216">Beneteau C, Cav&#x000e9; H, Moncla A, Dorison N, Munnich A, Verloes A, Leheup B. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:1216–21.</span> [<a href="/pmc/articles/PMC2986637/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986637</span></a>] [<a href="/pubmed/19352411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19352411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bentiresalj.2004.8816">Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <span><span class="ref-journal">Cancer Res. </span>2004;<span class="ref-vol">64</span>:8816–20.</span> [<a href="/pubmed/15604238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15604238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.berger.2014.4418">Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi GX, Andres DA, Meyerson M. Oncogenic RIT1 mutations in lung adenocarcinoma. <span><span class="ref-journal">Oncogene. </span>2014;<span class="ref-vol">33</span>:4418–23.</span> [<a href="/pmc/articles/PMC4150988/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4150988</span></a>] [<a href="/pubmed/24469055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24469055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bertola.2005.242">Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, Kim CA, Krieger JE. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">136</span>:242–5.</span> [<a href="/pubmed/15948193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15948193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bertola.2014.2952">Bertola DR, Yamamoto GL, Almeida TF, Buscarilli M, Jorge AA, Malaquias AC, Kim CA, Takahashi VN, Passos-Bueno MR, Pereira AC. Further evidence of the importance of RIT1 in Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:2952–7.</span> [<a href="/pubmed/25124994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25124994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.bigenzahn.2018.1171">Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, Sedlyarov V, Schischlik F, Fauster A, Rebsamen M, Parapatics K, Blomen VA, M&#x000fc;ller AC, Winter GE, Kralovics R, Brummelkamp TR, Mlodzik M, Superti-Furga G. LZTR1 is a regulator of RAS ubiquitination and signaling. <span><span class="ref-journal">Science. </span>2018;<span class="ref-vol">362</span>:1171–7.</span> [<a href="/pmc/articles/PMC6794158/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6794158</span></a>] [<a href="/pubmed/30442766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30442766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.binder.2005.5377">Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:5377–81.</span> [<a href="/pubmed/15985475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15985475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.brasil.2010.425">Brasil AS, Pereira AC, Wanderley LT, Kim CA, Malaquias AC, Jorge AA, Krieger JE, Bertola DR. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes. <span><span class="ref-journal">Genet Test Mol Biomarkers. </span>2010;<span class="ref-vol">14</span>:425–32.</span> [<a href="/pubmed/20578946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20578946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.briggs.2012.167">Briggs BJ, Dickerman JD. Bleeding disorders in Noonan syndrome. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2012;<span class="ref-vol">58</span>:167–72.</span> [<a href="/pubmed/22012616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22012616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cancer_genome_atlas_research_network.2014.543">Cancer Genome Atlas Research Network.  Comprehensive molecular profiling of lung adenocarcinoma. <span><span class="ref-journal">Nature. </span>2014;<span class="ref-vol">511</span>:543–50.</span> [<a href="/pmc/articles/PMC4231481/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4231481</span></a>] [<a href="/pubmed/25079552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25079552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.chen.2014a.28">Chen JL, Zhu X, Zhao TL, Wang J, Yang YF, Tan ZP. Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11. <span><span class="ref-journal">Mol Cytogenet. </span>2014a;<span class="ref-vol">7</span>:28.</span> [<a href="/pmc/articles/PMC4031927/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4031927</span></a>] [<a href="/pubmed/24739123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24739123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.chen.2014b.11473">Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, Yung CK, Trinh QM, Peltekova VD, Reid JG, Tworog-Dube E, Morgan MB. Muzny DM6, Stein L, McPherson JD, Roberts AE, Gibbs RA, Neel BG, Kucherlapati R. Next-generation sequencing identifies rare variants associated with Noonan syndrome. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2014b;<span class="ref-vol">111</span>:11473–8.</span> [<a href="/pmc/articles/PMC4128129/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4128129</span></a>] [<a href="/pubmed/25049390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25049390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cirstea.2010.27">Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, K&#x000f6;nig R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M. A restricted spectrum of NRAS mutations causes Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:27–9.</span> [<a href="/pmc/articles/PMC3118669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3118669</span></a>] [<a href="/pubmed/19966803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19966803</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.colley.1996.59">Colley A, Donnai D, Evans DG. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. <span><span class="ref-journal">Clin Genet. </span>1996;<span class="ref-vol">49</span>:59–64.</span> [<a href="/pubmed/8740913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8740913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cordeddu.2009.1022">Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, Cecchetti S, Cardinale A, Martin J, Schackwitz W, Lipzen A, Zampino G, Mazzanti L, Digilio MC, Martinelli S, Flex E, Lepri F, Bartholdi D, Kutsche K, Ferrero GB, Anichini C, Selicorni A, Rossi C, Tenconi R, Zenker M, Merlo D, Dallapiccola B, Iyengar R, Bazzicalupo P, Gelb BD, Tartaglia M. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. <span><span class="ref-journal">Nat Genet. </span>2009;<span class="ref-vol">41</span>:1022–6.</span> [<a href="/pmc/articles/PMC2765465/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2765465</span></a>] [<a href="/pubmed/19684605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19684605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.cordeddu.2015.1080">Cordeddu V, Yin JC, Gunnarsson C, Virtanen C, Drunat S, Lepri F, De Luca A, Rossi C, Ciolfi A, Pugh TJ, Bruselles A, Priest JR, Pennacchio LA, Lu Z, Danesh A, Quevedo R, Hamid A, Martinelli S, Pantaleoni F, Gnazzo M, Daniele P, Lissewski C, Bocchinfuso G, Stella L, Odent S, Philip N, Faivre L, Vlckova M, Seemanova E, Digilio C, Zenker M, Zampino G, Verloes A, Dallapiccola B, Roberts AE, Cav&#x000e9; H, Gelb BD, Neel BG, Tartaglia M. Activating mutations affecting the Dbl homology domain of SOS2 cause Noonan syndrome. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:1080–7.</span> [<a href="/pmc/articles/PMC4604019/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4604019</span></a>] [<a href="/pubmed/26173643" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26173643</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.dahlgren.2009.46">Dahlgren J. GH therapy in Noonan syndrome: review of final height data. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">72</span>:46–8.</span> [<a href="/pubmed/20029237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029237</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.de_filippi.2009.706">De Filippi P, Zecca M, Lisini D, Rosti V, Cagioni C, Carlo-Stella C, Radi O, Veggiotti P, Mastronuzzi A, Acquaviva A, D'Ambrosio A, Locatelli F, Danesino C. Germline mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">147</span>:706–9.</span> [<a href="/pubmed/19775298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19775298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.denayer.2010.242">Denayer E, Devriendt K, de Ravel T, Van Buggenhout G, Smeets E, Francois I, Sznajer Y, Craen M, Leventopoulos G, Mutesa L, Vandecasseye W, Massa G, Kayserili H, Sciot R, Fryns JP, Legius E. Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2010;<span class="ref-vol">49</span>:242–52.</span> [<a href="/pubmed/19953625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19953625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.denayer.2012.34">Denayer E, Peeters H, Sevenants L, Derbent M, Fryns JP, Legius E. NRAS mutations in Noonan syndrome. <span><span class="ref-journal">Mol Syndromol. </span>2012;<span class="ref-vol">3</span>:34–8.</span> [<a href="/pmc/articles/PMC3398822/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3398822</span></a>] [<a href="/pubmed/22855653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22855653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.derbent.2010.2768">Derbent M, Oncel Y, Tokel K, Varan B, Haberal A, Yazici AC, Legius E, Ozbek N. Clinical and hematological findings in Noonan syndrome patients with PTPN11 mutations. <span><span class="ref-journal">Am J Med Genet. </span>2010;<span class="ref-vol">152A</span>:2768–74.</span> [<a href="/pubmed/20954246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20954246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ejarque.2015.408">Ejarque I, Mill&#x000e1;n-Salvador JM, Oltra S, Pesudo-Mart&#x000ed;nez JV, Beneyto M, P&#x000e9;rez-Ayt&#x000e9;s A. Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway. <span><span class="ref-journal">Rev Neurol. </span>2015;<span class="ref-vol">60</span>:408–12.</span> [<a href="/pubmed/25912702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25912702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ekvall.2015.95">Ekvall S, Wilbe M, Dahlgren J, Legius E, van Haeringen A, Westphal O, Anner&#x000e9;n G, Bondeson ML. Mutation in NRAS in familial Noonan syndrome - case report and review of the literature. <span><span class="ref-journal">BMC Med Genet. </span>2015;<span class="ref-vol">16</span>:95.</span> [<a href="/pmc/articles/PMC4607013/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4607013</span></a>] [<a href="/pubmed/26467218" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26467218</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.estep.2007.e1279">Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. <span><span class="ref-journal">PLoS One. </span>2007;<span class="ref-vol">2</span>:e1279.</span> [<a href="/pmc/articles/PMC2093994/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2093994</span></a>] [<a href="/pubmed/18060073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18060073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ferreira.2005.5156">Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:5156–60.</span> [<a href="/pubmed/15956085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15956085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.flex.2014.4315">Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa EK, Caye A, De Luca A, Lepri F, Dvorsky R, Pannone L, Paolacci S, Zhang SC, Fodale V, Bocchinfuso G, Rossi C, Burkitt-Wright EM, Farrotti A, Stellacci E, Cecchetti S, Ferese R, Bottero L, Castro S, Fenneteau O, Brethon B, Sanchez M, Roberts AE, Yntema HG, Van Der Burgt I, Cianci P, Bondeson ML, Cristina Digilio M, Zampino G, Kerr B, Aoki Y, Loh ML, Palleschi A, Di Schiavi E, Car&#x000e8; A, Selicorni A, Dallapiccola B, Cirstea IC, Stella L, Zenker M, Gelb BD, Cav&#x000e9; H, Ahmadian MR, Tartaglia M. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:4315–27.</span> [<a href="/pmc/articles/PMC4103678/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4103678</span></a>] [<a href="/pubmed/24705357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24705357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.fragale.2004.267">Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. <span><span class="ref-journal">Hum Mutat. </span>2004;<span class="ref-vol">23</span>:267–77.</span> [<a href="/pubmed/14974085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14974085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.gandhi.2004.183">Gandhi SV, Howarth ES, Krarup KC, Konje JC. Noonan syndrome presenting with transient cystic hygroma. <span><span class="ref-journal">J Obstet Gynaecol. </span>2004;<span class="ref-vol">24</span>:183–4.</span> [<a href="/pubmed/14766467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14766467</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.graham.2009.2122">Graham JM Jr, Kramer N, Bejjani BA, Thiel CT, Carta C, Neri G, Tartaglia M, Zenker M. Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2009;<span class="ref-vol">149A</span>:2122–8.</span> [<a href="/pmc/articles/PMC2768228/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2768228</span></a>] [<a href="/pubmed/19760651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19760651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.gripp.2006.1">Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. <span><span class="ref-journal">Am J Med Genet A. </span>2006;<span class="ref-vol">140</span>:1–7.</span> [<a href="/pubmed/16329078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16329078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.guerin.2015.403">Guerin A, So J, Mireskandari K, Jougeh-Doust S, Chisholm C, Klatt R, Richer J. Expanding the clinical spectrum of ocular anomalies in Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation. <span><span class="ref-journal">Am J Med Genet A. </span>2015;<span class="ref-vol">167A</span>:403–6.</span> [<a href="/pubmed/25425531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25425531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hart.2002.943">Hart TC, Zhang Y, Gorry MC, Hart PS, Cooper M, Marazita ML, Marks JM, Cortelli JR, Pallos D. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:943–54.</span> [<a href="/pmc/articles/PMC379122/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379122</span></a>] [<a href="/pubmed/11868160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11868160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hasle.2009.8">Hasle H. Malignant diseases in Noonan syndrome and related disorders. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">72</span>:8–14.</span> [<a href="/pubmed/20029231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hastings.2010.967">Hastings R, Newbury-Ecob R, Ng A, Taylor R. A further patient with Noonan syndrome due to a SOS1 mutation and rhabdomyosarcoma. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2010;<span class="ref-vol">49</span>:967–8.</span> [<a href="/pubmed/20607846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20607846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hennekam.2003.42">Hennekam RC. Costello syndrome: an overview. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2003;<span class="ref-vol">117C</span>:42–8.</span> [<a href="/pubmed/12561057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12561057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hickey.2011.41">Hickey EJ, Mehta R, Elmi M, Asoh K, McCrindle BW, Williams WG, Manlhiot C, Benson L. Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. <span><span class="ref-journal">Congenit Heart Dis. </span>2011;<span class="ref-vol">6</span>:41–7.</span> [<a href="/pubmed/21269411" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21269411</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.higgins.2017.e91225">Higgins EM, Bos JM, Mason-Suares H, Tester DJ, Ackerman JP, MacRae CA, Sol-Church K, Gripp KW, Urrutia R, Ackerman MJ. Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. <span><span class="ref-journal">JCI Insight. </span>2017;<span class="ref-vol">2</span>:e91225.</span> [<a href="/pmc/articles/PMC5333962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5333962</span></a>] [<a href="/pubmed/28289718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28289718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.hiippala.2001.18">Hiippala A, Eronen M, Taipale P, Salonen R, Hiilesmaa V. Fetal nuchal translucency and normal chromosomes: a long-term follow-up study. <span><span class="ref-journal">Ultrasound Obstet Gynecol. </span>2001;<span class="ref-vol">18</span>:18–22.</span> [<a href="/pubmed/11489219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11489219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.houweling.2010.284">Houweling AC, de Mooij YM, van der Burgt I, Yntema HG, Lachmeijer AM, Go AT. Prenatal detection of Noonan syndrome by mutation analysis of the PTPN11 and the KRAS genes. <span><span class="ref-journal">Prenat Diagn. </span>2010;<span class="ref-vol">30</span>:284–6.</span> [<a href="/pubmed/20112233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20112233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jacquinet.2019">Jacquinet A, Bonnard A, Capri Y, Martin D, Sadzot B, Bianchi E, Servais L, Sacr&#x000e9; JP, Cav&#x000e9; H, Verloes A. Oligo-astrocytoma in LZTR1-related Noonan syndrome. <span><span class="ref-journal">Eur J Med Genet. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/30664951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30664951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jafarov.2005.190">Jafarov T, Ferimazova N, Reichenberger E. Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. <span><span class="ref-journal">Clin Genet. </span>2005;<span class="ref-vol">68</span>:190–1.</span> [<a href="/pubmed/15996221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15996221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.johnston.2018.1175">Johnston JJ, van der Smagt JJ, Rosenfeld JA, Pagnamenta AT, Alswaid A, Baker EH, Blair E, Borck G, Brinkmann J, Craigen W, Dung VC, Emrick L, Everman DB, van Gassen KL, Gulsuner S, Harr MH, Jain M, Kuechler A, Leppig KA, McDonald-McGinn DM, Can NTB, Peleg A, Roeder ER, Rogers RC, Sagi-Dain L, Sapp JC, Sch&#x000e4;ffer AA, Schanze D, Stewart H, Taylor JC, Verbeek NE, Walkiewicz MA, Zackai EH, Zweier C, Zenker M, Lee B, Biesecker LG, et al.  Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. <span><span class="ref-journal">Genet Med. </span>2018;<span class="ref-vol">20</span>:1175–85.</span> [<a href="/pmc/articles/PMC6105555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6105555</span></a>] [<a href="/pubmed/29469822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29469822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2004.56">Jongmans M, Otten B, Noordam K, van der Burgt I. Genetics and variation in phenotype in Noonan syndrome. <span><span class="ref-journal">Horm Res. </span>2004;<span class="ref-vol">62</span> Suppl 3:56–9.</span> [<a href="/pubmed/15539800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15539800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2010.635">Jongmans MC, Hoogerbrugge PM, Hilkens L, Flucke U, van der Burgt I, Noordam K, Ruiterkamp-Versteeg M, Yntema HG, Nillesen WM, Ligtenberg MJ, van Kessel AG, Kuiper RP, Hoogerbrugge N. Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2010;<span class="ref-vol">49</span>:635–41.</span> [<a href="/pubmed/20461756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20461756</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jongmans.2011.870">Jongmans MC, van der Burgt I, Hoogerbrugge PM, Noordam K, Yntema HG, Nillesen WM, Kuiper RP, Ligtenberg MJ, van Kessel AG, van Krieken JH, Kiemeney LA, Hoogerbrugge N. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:870–4.</span> [<a href="/pmc/articles/PMC3172922/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3172922</span></a>] [<a href="/pubmed/21407260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21407260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jo_.2005.373">Jo&#x000f3; JG, Beke A, T&#x000f3;th-P&#x000e1;l E, Csaba A, Papp C. Successful pregnancy in a Noonan syndrome patient after 3 unsuccessful pregnancies from severe fetal hydrops: a case report. <span><span class="ref-journal">J Reprod Med. </span>2005;<span class="ref-vol">50</span>:373–6.</span> [<a href="/pubmed/15971489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15971489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.jung.2003.330">Jung A, Bechthold S, Pfluger T, Renner C, Ehrt O. Orbital rhabdomyosarcoma in Noonan syndrome. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2003;<span class="ref-vol">25</span>:330–2.</span> [<a href="/pubmed/12679651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12679651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.keh.2013.749">Keh YS, Abernethy L, Pettorini B. Association between Noonan syndrome and Chiari I malformation: a case-based update. <span><span class="ref-journal">Childs Nerv Syst. </span>2013;<span class="ref-vol">29</span>:749–52.</span> [<a href="/pubmed/23239255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23239255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kerr.2006.401">Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cav&#x000e9; H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:401–5.</span> [<a href="/pmc/articles/PMC2564514/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564514</span></a>] [<a href="/pubmed/16443854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16443854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.khan.1995.743">Khan S, McDowell H, Upadhyaya M, Fryer A. Vaginal rhabdomyosarcoma in a patient with Noonan syndrome. <span><span class="ref-journal">J Med Genet. </span>1995;<span class="ref-vol">32</span>:743–5.</span> [<a href="/pmc/articles/PMC1051679/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051679</span></a>] [<a href="/pubmed/8544198" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8544198</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.koudova.2009.337">Koudova M, Seemanova E, Zenker M. Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence. <span><span class="ref-journal">Eur J Med Genet. </span>2009;<span class="ref-vol">52</span>:337–40.</span> [<a href="/pubmed/19416762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19416762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kraoua.2012.2407">Kraoua L, Journel H, Bonnet P, Amiel J, Pouvreau N, Baumann C, Verloes A, Cav&#x000e9; H. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:2407–11.</span> [<a href="/pubmed/22887781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22887781</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2015.1392">Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schl&#x000fc;ter G, Gencik M, &#x000dc;berlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. <span><span class="ref-journal">Br J Cancer. </span>2015;<span class="ref-vol">112</span>:1392–7.</span> [<a href="/pmc/articles/PMC4402457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4402457</span></a>] [<a href="/pubmed/25742478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25742478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2005.2183">Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstr&#x000e4;sser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:2183–5.</span> [<a href="/pmc/articles/PMC1895140/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1895140</span></a>] [<a href="/pubmed/15928039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15928039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2007.227">Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. <span><span class="ref-journal">J Mol Med (Berl). </span>2007;<span class="ref-vol">85</span>:227–35.</span> [<a href="/pmc/articles/PMC1820751/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1820751</span></a>] [<a href="/pubmed/17211612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17211612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.kratz.2009.1036">Kratz CP, Zampino G, Kriek M, Kant SG, Leoni C, Pantaleoni F, Oudesluys-Murphy AM, Di Rocco C, Kloska SP, Tartaglia M, Zenker M. Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1036–40.</span> [<a href="/pubmed/19396835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19396835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2014.1171">Lee A, Sakhalkar MV. Ocular manifestations of Noonan syndrome in twin siblings: a case report of keratoconus with acute corneal hydrops. <span><span class="ref-journal">Indian J Ophthalmol. </span>2014;<span class="ref-vol">62</span>:1171–3.</span> [<a href="/pmc/articles/PMC4313503/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4313503</span></a>] [<a href="/pubmed/25579364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25579364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.1996.6784">Lee CH, Della NG, Chew CE, Zack DJ. Rin, a neuron-specific and calmodulin-binding small G-protein, and Rit define a novel subfamily of ras proteins. <span><span class="ref-journal">J Neurosci. </span>1996;<span class="ref-vol">16</span>:6784–94.</span> [<a href="/pmc/articles/PMC6579259/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6579259</span></a>] [<a href="/pubmed/8824319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8824319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2005a.35">Lee DA, Portnoy S, Hill P, Gillberg C, Patton MA. Psychological profile of children with Noonan syndrome. <span><span class="ref-journal">Dev Med Child Neurol. </span>2005a;<span class="ref-vol">47</span>:35–8.</span> [<a href="/pubmed/15686287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15686287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2009.190">Lee KA, Williams B, Roza K, Ferguson H, David K, Eddleman K, Stone J, Edelmann L, Richard G, Gelb BD, Kornreich R. PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">75</span>:190–4.</span> [<a href="/pubmed/18759865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18759865</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2015.17">Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, Christesen HT. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-na&#x000ef;ve patients enrolled in the NordiNet&#x000ae; International Outcome Study and the ANSWER Program. <span><span class="ref-journal">Int J Pediatr Endocrinol. </span>2015;<span class="ref-vol">2015</span>:17.</span> [<a href="/pmc/articles/PMC4562101/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4562101</span></a>] [<a href="/pubmed/26351466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26351466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lee.2005b.7">Lee WH, Raas-Rotschild A, Miteva MA, Bolasco G, Rein A, Gillis D, Vidaud D, Vidaud M, Villoutreix BO, Parfait B. Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications. <span><span class="ref-journal">Proteins. </span>2005b;<span class="ref-vol">58</span>:7–13.</span> [<a href="/pubmed/15521065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15521065</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.limal.2006.300">Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y. Noonan syndrome: Relationships between genotype, growth, and growth factors. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:300–6.</span> [<a href="/pubmed/16263833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16263833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.lissewski.2015.2685">Lissewski C, Kant SG, Stark Z, Schanze I, Zenker M. Copy number variants including RAS pathway genes-how much RASopathy is in the phenotype? <span><span class="ref-journal">Am J Med Genet A. </span>2015;<span class="ref-vol">167A</span>:2685–90.</span> [<a href="/pubmed/25974318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25974318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.luo.2012.1918">Luo C, Yang YF, Yin BL, Chen JL, Huang C, Zhang WZ, Wang J, Zhang H, Yang JF, Tan ZP. Microduplication of 3p25.2 encompassing RAF1 associated with congenital heart disease suggestive of Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:1918–23.</span> [<a href="/pubmed/22786616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22786616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.marcus.2008.1079">Marcus KA, Sweep CG, van der Burgt I, Noordam C. Impaired Sertoli cell function in males diagnosed with Noonan syndrome. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>2008;<span class="ref-vol">21</span>:1079–84.</span> [<a href="/pubmed/19189703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19189703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.marks.2008.5524">Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. <span><span class="ref-journal">Cancer Res. </span>2008;<span class="ref-vol">68</span>:5524–8.</span> [<a href="/pmc/articles/PMC2586155/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2586155</span></a>] [<a href="/pubmed/18632602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18632602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.martinelli.2010.250">Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F, Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, Screpanti I, Yntema HG, Nillesen WM, Savarirayan R, Zenker M, Dallapiccola B, Gelb BD, Tartaglia M. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">87</span>:250–7.</span> [<a href="/pmc/articles/PMC2917705/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2917705</span></a>] [<a href="/pubmed/20619386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20619386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.martinelli.2015.787">Martinelli S, Stellacci E, Pannone L, D'Agostino D, Consoli F, Lissewski C, Silvano M, Cencelli G, Lepri F, Maitz S, Pauli S, Rauch A, Zampino G, Selicorni A, Melan&#x000e7;on S, Digilio MC, Gelb BD, De Luca A, Dallapiccola B, Zenker M, Tartaglia M. Molecular diversity and associated phenotypic spectrum of germline CBL mutations. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:787–96.</span> [<a href="/pubmed/25952305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25952305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.menashe.2002.51">Menashe M, Arbel R, Raveh D, Achiron R, Yagel S. Poor prenatal detection rate of cardiac anomalies in Noonan syndrome. <span><span class="ref-journal">Ultrasound Obstet Gynecol. </span>2002;<span class="ref-vol">19</span>:51–5.</span> [<a href="/pubmed/11851968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11851968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.mitsuhara.2014.6">Mitsuhara T, Yamaguchi S, Takeda M, Kurisu K. Gowers' intrasyringeal hemorrhage associated with Chiari type I malformation in Noonan syndrome. <span><span class="ref-journal">Surg Neurol Int. </span>2014;<span class="ref-vol">5</span>:6.</span> [<a href="/pmc/articles/PMC3927095/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3927095</span></a>] [<a href="/pubmed/24575321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24575321</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.moschovi.2007.341">Moschovi M, Touliatou V, Papadopoulou A, Mayakou MA, Nikolaidou-Karpathiou P, Kitsiou-Tzeli S. Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2007;<span class="ref-vol">29</span>:341–4.</span> [<a href="/pubmed/17483716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17483716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.motta.2019.1007">Motta M, Fidan M, Bellacchio E, Pantaleoni F, Schneider-Heieck K, Coppola S, Borck G, Salviati L, Zenker M, Cirstea IC, Tartaglia M. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. <span><span class="ref-journal">Hum Mol Genet. </span>2019;<span class="ref-vol">28</span>:1007–22.</span> [<a href="/pubmed/30481304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30481304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.myers.2014.2814">Myers A, Bernstein JA, Brennan ML, Curry C, Esplin ED, Fisher J, Homeyer M, Manning MA, Muller EA, Niemi AK, Seaver LH, Hintz SR, Hudgins L. Perinatal features of the RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:2814–21.</span> [<a href="/pubmed/25250515" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25250515</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nakaguma.2019.260">Nakaguma M, Jorge AAL, Arnhold IJP. Noonan syndrome associated with growth hormone deficiency with biallelic LZTR1 variants. <span><span class="ref-journal">Genet Med. </span>2019;<span class="ref-vol">21</span>:260.</span> [<a href="/pubmed/29959388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29959388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.narumi.2008.834">Narumi Y, Aoki Y, Niihori T, Sakurai M, Cav&#x000e9; H, Verloes A, Nishio K, Ohashi H, Kurosawa K, Okamoto N, Kawame H, Mizuno S, Kondoh T, Addor MC, Coeslier-Dieux A, Vincent-Delorme C, Tabayashi K, Aoki M, Kobayashi T, Guliyeva A, Kure S, Matsubara Y. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. <span><span class="ref-journal">J Hum Genet. </span>2008;<span class="ref-vol">53</span>:834–41.</span> [<a href="/pubmed/18651097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18651097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nava.2007.763">Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, Heron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, Cave H. CFC and Noonan syndromes due to mutations in RAS/MAPK signaling pathway: genotype/phenotype relationships and overlap with Costello syndrome. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:763–71.</span> [<a href="/pmc/articles/PMC2652823/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2652823</span></a>] [<a href="/pubmed/17704260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17704260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.neumann.2009.420">Neumann TE, Allanson J, Kavamura I, Kerr B, Neri G, Noonan J, Cordeddu V, Gibson K, Tzschach A, Kr&#x000fc;ger G, Hoeltzenbein M, Goecke TO, Kehl HG, Albrecht B, Luczak K, Sasiadek MM, Musante L, Laurie R, Peters H, Tartaglia M, Zenker M, Kalscheuer V. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:420–5.</span> [<a href="/pmc/articles/PMC2986220/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986220</span></a>] [<a href="/pubmed/18854871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18854871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niemeyer.2010.794">Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Star&#x000fd; J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:794–800.</span> [<a href="/pmc/articles/PMC4297285/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4297285</span></a>] [<a href="/pubmed/20694012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20694012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.niihori.2005.192">Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriyama S, Kawame H, Kamasaki H, Yamanaka T, Takada F, Nishio K, Sakurai M, Tamai H, Nagashima T, Suzuki Y, Kure S, Fujii K, Imaizumi M, Matsubara Y. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. <span><span class="ref-journal">J Hum Genet. </span>2005;<span class="ref-vol">50</span>:192–202.</span> [<a href="/pubmed/15834506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15834506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nisbet.1999.642">Nisbet DL, Griffin DR, Chitty LS. Prenatal features of Noonan syndrome. <span><span class="ref-journal">Prenat Diagn. </span>1999;<span class="ref-vol">19</span>:642–7.</span> [<a href="/pubmed/10419612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10419612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.2001">Noonan JA (2001) Cardiac findings in cardio-facio-cutaneous syndrome: similarities to Noonan and Costello syndromes. Proc Greenwood Gen Ctr.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.a">Noonan JA. Noonan syndrome. In: Goldstein S, Reynolds CR, eds. <em>Handbook of Neurodevelopmental and Genetic Disorders in Adults.</em> New York: Guilford Press; 2005a:308-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.2005b.177">Noonan JA. Noonan syndrome and related disorders. <span><span class="ref-journal">Prog Pediatr Cardiol. </span>2005b;<span class="ref-vol">20</span>:177–85.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noonan.2003.68">Noonan JA, Raaijmakers R, Hall BD. Adult height in Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">123A</span>:68–71.</span> [<a href="/pubmed/14556249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14556249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF97">Noonan Syndrome Guideline Development Group. <em>Management of Noonan Syndrome &#x02013; A Clinical Guideline</em>. University of Manchester: DYSCERNE. Available <a href="https://rasopathiesnet.org/wp-content/uploads/2014/01/265_Noonan_Guidelines.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 8-1-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noordam.2008.203">Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. <span><span class="ref-journal">Eur J Endocrinol. </span>2008;<span class="ref-vol">159</span>:203–8.</span> [<a href="/pubmed/18562489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18562489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.noordam.2007.24">Noordam K. Expanding the genetic spectrum of Noonan syndrome. <span><span class="ref-journal">Horm Res. </span>2007;<span class="ref-vol">68</span>:24–7.</span> [<a href="/pubmed/18174700" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18174700</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nystr_m.2008.500">Nystr&#x000f6;m A-M, Ekvall S, Berglund E, Bj&#x000f6;rkvist M, Braathen G, Duchen K, Enell H, Holmberg E, Holmlund U, Olsson-Engman M, Anner&#x000e9;n G, Bondeson M-L. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. <span><span class="ref-journal">J Med Genet. </span>2008;<span class="ref-vol">45</span>:500–6.</span> [<a href="/pubmed/18456719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18456719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.nystr_m.2009.524">Nystr&#x000f6;m AM, Ekvall S, Allanson J, Edeby C, Elinder M, Holmstr&#x000f6;m G, Bondeson ML, Anner&#x000e9;n G. Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">76</span>:524–34.</span> [<a href="/pubmed/19845691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19845691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.ogawa.2004.61">Ogawa M, Moriya N, Ikeda H, Tanae A, Tanaka T, Ohyama K, Mori O, Yazawa T, Fujita K, Seino Y, Kubo T, Tanaka H, Nishi Y, Yoshimoto M. Clinical evaluation of recombinant human growth hormone in Noonan syndrome. <span><span class="ref-journal">Endocr J. </span>2004;<span class="ref-vol">51</span>:61–8.</span> [<a href="/pubmed/15004410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15004410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.osio.2005.1232">Osio D, Dahlgren J, Wikland KA, Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. <span><span class="ref-journal">Acta Paediatr. </span>2005;<span class="ref-vol">94</span>:1232–7.</span> [<a href="/pubmed/16203673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16203673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.otten.2009.31">Otten BJ, Noordam C. Growth in Noonan syndrome. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">72</span>:31–5.</span> [<a href="/pubmed/20029234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pagnamenta.2019.693">Pagnamenta AT, Kaisaki PJ, Bennett F, Burkitt-Wright E, Martin HC, Ferla MP, Taylor JM, Gompertz L, Lahiri N, Tatton-Brown K, Newbury-Ecob R, Henderson A, Joss S, Weber A, Carmichael J, Turnpenny PD, McKee S, Forzano F, Ashraf T, Bradbury K, Shears D, Kini U, de Burca A, Blair E, Taylor JC, Stewart H, et al.  Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome. <span><span class="ref-journal">Clin Genet. </span>2019;<span class="ref-vol">95</span>:693–703.</span> [<a href="/pmc/articles/PMC6563422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6563422</span></a>] [<a href="/pubmed/30859559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30859559</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pandit.2007.1007">Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, L&#x000f3;pez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:1007–12.</span> [<a href="/pubmed/17603483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17603483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.perin.2019">Perin F, Trujillo-Quintero JP, Jimenez-Jaimez J, Rodr&#x000ed;guez-V&#x000e1;zquez Del Rey MDM, Monserrat L, Tercedor L. Two novel cases of autosomal recessive Noonan syndrome associated with LZTR1 variants. Rev Esp Cardiol (Engl Ed). 2019. Epub ahead of print. [<a href="/pubmed/31182298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31182298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2016">Pierpont EI. Neuropsychological functioning in individuals with Noonan syndrome: a systematic literature review with educational and treatment recommendations. J Pediatr Neuropsychol. 2016;2:14-33. Available <a href="http://link.springer.com/article/10.1007/s40817-015-0005-5/fulltext.html" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. Accessed 8-1-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2010a.591">Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Rauen KA, Seidenberg MS. Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2010a;<span class="ref-vol">152A</span>:591–600.</span> [<a href="/pmc/articles/PMC3085983/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3085983</span></a>] [<a href="/pubmed/20186801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20186801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2009.275">Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Seidenberg MS. Genotype differences in cognitive functioning in Noonan syndrome. <span><span class="ref-journal">Genes Brain Behav. </span>2009;<span class="ref-vol">8</span>:275–82.</span> [<a href="/pmc/articles/PMC2760992/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2760992</span></a>] [<a href="/pubmed/19077116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19077116</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2015.385">Pierpont EI, Tworog-Dube E, Roberts AE. Attention skills and executive functioning in children with Noonan syndrome and their unaffected siblings. <span><span class="ref-journal">Dev Med Child Neurol. </span>2015;<span class="ref-vol">57</span>:385–92.</span> [<a href="/pubmed/25366258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25366258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.pierpont.2010b.917">Pierpont EI, Weismer SE, Roberts AE, Tworog-Dube E, Pierpont ME, Mendelsohn NJ, Seidenberg MS. The language phenotype of children and adolescents with Noonan syndrome. <span><span class="ref-journal">J Speech Lang Hear Res. </span>2010b;<span class="ref-vol">53</span>:917–32.</span> [<a href="/pmc/articles/PMC3086511/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3086511</span></a>] [<a href="/pubmed/20543023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20543023</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.piotrowski.2014.182">Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, Fu C, Crowley MR, Crossman DK, Armstrong L, Babovic-Vuksanovic D, Bergner A, Blakeley JO, Blumenthal AL, Daniels MS, Feit H, Gardner K, Hurst S, Kobelka C, Lee C, Nagy R, Rauen KA, Slopis JM, Suwannarat P, Westman JA, Zanko A, Korf BR, Messiaen LM. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. <span><span class="ref-journal">Nat Genet. </span>2014;<span class="ref-vol">46</span>:182–7.</span> [<a href="/pmc/articles/PMC4352302/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4352302</span></a>] [<a href="/pubmed/24362817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24362817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.prendiville.2014.629">Prendiville TW, Gauvreau K, Tworog-Dube E, Patkin L, Kucherlapati RS, Roberts AE, Lacro RV. Cardiovascular disease in Noonan syndrome. <span><span class="ref-journal">Arch Dis Child. </span>2014;<span class="ref-vol">99</span>:629–34.</span> [<a href="/pubmed/24534818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24534818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.reynders.1997.101">Reynders CS, Pauker SP, Benacerraf BR. First trimester isolated fetal nuchal lucency: significance and outcome. <span><span class="ref-journal">J Ultrasound Med. </span>1997;<span class="ref-vol">16</span>:101–5.</span> [<a href="/pubmed/9166801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9166801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.roberts.2013.333_1">Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>:333–42.</span> [<a href="/pmc/articles/PMC4267483/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4267483</span></a>] [<a href="/pubmed/23312968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23312968</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.roberts.2007.70">Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:70–4.</span> [<a href="/pubmed/17143285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.romano.2010.746_1">Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. <span><span class="ref-journal">Pediatrics. </span>2010;<span class="ref-vol">126</span>:746–59.</span> [<a href="/pubmed/20876176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20876176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.romano.2009.2338">Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J, Lippe B. Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:2338–44.</span> [<a href="/pubmed/19401366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19401366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.runtuwene.2011.393">Runtuwene V, van Eekelen M, Overvoorde J, Rehmann H, Yntema HG, Nillesen WM, et al.  Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. <span><span class="ref-journal">Dis Model Mech. </span>2011;<span class="ref-vol">4</span>:393–9.</span> [<a href="/pmc/articles/PMC3097460/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3097460</span></a>] [<a href="/pubmed/21263000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21263000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sana.2014.2069">Sana ME, Spitaleri A, Spiliotopoulos D, Pezzoli L, Preda L, Musco G, Ferrazzi P, Iascone M. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2014;<span class="ref-vol">164A</span>:2069–73.</span> [<a href="/pubmed/24782337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24782337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sarkozy.2009.695">Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM, Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L, Stanzial F, Faravelli F, Stuppia L, Puxeddu E, Gelb BD, Dallapiccola B, Tartaglia M. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:695–702.</span> [<a href="/pmc/articles/PMC4028130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4028130</span></a>] [<a href="/pubmed/19206169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19206169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.schl_ter.2005.574">Schl&#x000fc;ter G, Steckel M, Schiffmann H, Harms K, Viereck V, Emons G, Burfeind P, Pauer HU. Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites. <span><span class="ref-journal">Prenat Diagn. </span>2005;<span class="ref-vol">25</span>:574–6.</span> [<a href="/pubmed/16032767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16032767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.schubbert.2006.331">Schubbert S, Zenker M, Rowe SL, B&#x000f6;ll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:331–6.</span> [<a href="/pubmed/16474405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16474405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sharland.1992.178">Sharland M, Burch M, McKenna WM, Paton MA. A clinical study of Noonan syndrome. <span><span class="ref-journal">Arch Dis Child. </span>1992;<span class="ref-vol">67</span>:178–83.</span> [<a href="/pmc/articles/PMC1793396/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1793396</span></a>] [<a href="/pubmed/1543375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1543375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.shchelochkov.2008.1042">Shchelochkov OA, Patel A, Weissenberger GM, Chinault AC, Wiszniewska J, Fernandes PH, Eng C, Kukolich MK, Sutton VR. Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:1042–8.</span> [<a href="/pubmed/18348260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18348260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.shaw.2007.128">Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan syndrome: a long-term follow-up study. <span><span class="ref-journal">Arch Dis Child. </span>2007;<span class="ref-vol">92</span>:128–32.</span> [<a href="/pmc/articles/PMC2083343/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2083343</span></a>] [<a href="/pubmed/16990350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16990350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.sithanandam.1990.1775">Sithanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. <span><span class="ref-journal">Oncogene. </span>1990;<span class="ref-vol">5</span>:1775–80.</span> [<a href="/pubmed/2284096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2284096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.smpokou.2012.3106">Smpokou P, Tworog-Dube E, Kucherlapati RS, Roberts AE. Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2012;<span class="ref-vol">158A</span>:3106–11.</span> [<a href="/pubmed/23165751" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23165751</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.soisson.1998.259">Soisson SM, Nimnual AS, Uy M, Bar-Sagi D, Kuriyan J. Crystal structure of the Dbl and pleckstrin homology domains from the human Son of sevenless protein. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">95</span>:259–68.</span> [<a href="/pubmed/9790532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9790532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.solit.2006.358">Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">439</span>:358–62.</span> [<a href="/pmc/articles/PMC3306236/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3306236</span></a>] [<a href="/pubmed/16273091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16273091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.steklov.2018.1177">Steklov M, Pandolfi S, Baietti MF, Batiuk A, Carai P, Najm P, Zhang M, Jang H, Renzi F, Cai Y, Abbasi Asbagh L, Pastor T, De Troyer M, Simicek M, Radaelli E, Brems H, Legius E, Tavernier J, Gevaert K, Impens F, Messiaen L, Nussinov R, Heymans S, Eyckerman S, Sablina AA. Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. <span><span class="ref-journal">Science. </span>2018;<span class="ref-vol">362</span>:1177–82.</span> [<a href="/pubmed/30442762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30442762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.stevenson.2006.246">Stevenson DA, Viskochil DH, Rope AF, Carey JC. Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. <span><span class="ref-journal">Clin Genet. </span>2006;<span class="ref-vol">69</span>:246–53.</span> [<a href="/pmc/articles/PMC3243644/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3243644</span></a>] [<a href="/pubmed/16542390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16542390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.suzuki.2019.1628">Suzuki H, Takenouchi T, Uehara T, Takasago S, Ihara S, Yoshihashi H, Kosaki K. Severe Noonan syndrome phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers. <span><span class="ref-journal">Am J Med Genet A. </span>2019;<span class="ref-vol">179</span>:1628–30.</span> [<a href="/pubmed/31173466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31173466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2004a.492">Tartaglia M, Cordeddu V, Chang H, Shaw A, Kalidas K, Crosby A, Patton MA, Sorcini M, van der Burgt I, Jeffery S, Gelb BD. Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2004a;<span class="ref-vol">75</span>:492–7.</span> [<a href="/pmc/articles/PMC1182027/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182027</span></a>] [<a href="/pubmed/15248152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15248152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2003a.423">Tartaglia M, Cotter PD, Zampino G, Gelb BD, Rauen KA. Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes. <span><span class="ref-journal">Clin Genet. </span>2003a;<span class="ref-vol">63</span>:423–6.</span> [<a href="/pubmed/12752577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12752577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2002.1555">Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:1555–63.</span> [<a href="/pmc/articles/PMC379142/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379142</span></a>] [<a href="/pubmed/11992261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11992261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2004b.307">Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Aric&#x000f2; M, Masera G, Basso G, Sorcini M, Gelb BD, Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. <span><span class="ref-journal">Blood. </span>2004b;<span class="ref-vol">104</span>:307–13.</span> [<a href="/pubmed/14982869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14982869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2001.465">Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">29</span>:465–8.</span> [<a href="/pubmed/11704759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11704759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2003b.148">Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, H&#x000e4;hlen K, Hasle H, Licht JD, Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. <span><span class="ref-journal">Nat Genet. </span>2003b;<span class="ref-vol">34</span>:148–50.</span> [<a href="/pubmed/12717436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12717436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tartaglia.2007.75">Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:75–9.</span> [<a href="/pubmed/17143282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17143282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tofil.2005.352">Tofil NM, Winkler MK, Watts RG, Noonan J. The use of recombinant factor VIIa in a patient with Noonan syndrome and life-threatening bleeding. <span><span class="ref-journal">Pediatr Crit Care Med. </span>2005;<span class="ref-vol">6</span>:352–4.</span> [<a href="/pubmed/15857538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15857538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.tr_ger.2003.82">Tr&#x000f6;ger B, Kutsche K, Bolz H, L&#x000fc;ttgen S, Gal A, Almassy Z, Caliebe A, Freisinger P, Hobbiebrunken E, Morlot M, Stefanova M, Streubel B, Wieczorek D, Meinecke P. No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">121A</span>:82–4.</span> [<a href="/pubmed/12900909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12900909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.umeki.2019.21">Umeki I, Niihori T, Abe T, Kanno SI, Okamoto N, Mizuno S, Kurosawa K, Nagasaki K, Yoshida M, Ohashi H, Inoue SI, Matsubara Y, Fujiwara I, Kure S, Aoki Y. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes. <span><span class="ref-journal">Hum Genet. </span>2019;<span class="ref-vol">138</span>:21–35.</span> [<a href="/pubmed/30368668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30368668</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_der_burgt.2007.4">van der Burgt I. Noonan syndrome. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2007;<span class="ref-vol">2</span>:4.</span> [<a href="/pmc/articles/PMC1781428/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1781428</span></a>] [<a href="/pubmed/17222357" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17222357</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.van_der_burgt.1999.707">van der Burgt I, Thoonen G, Roosenboom N, Assman-Hulsmans C, Gabreels F, Otten B, Brunner HG. Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">135</span>:707–13.</span> [<a href="/pubmed/10586173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10586173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.verhoeven.2008.191">Verhoeven W, Wingberm&#x000fc;hle E, Egger J, Van der Burgt I, Tuinier S. Noonan syndrome: psychological and psychiatric aspects. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:191–6.</span> [<a href="/pubmed/18080322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18080322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.vissers.2015.317">Vissers LE, Bonetti M, Paardekooper Overman J, Nillesen WM, Frints SG, de Ligt J, Zampino G, Justino A, Machado JC, Schepens M, Brunner HG, Veltman JA, Scheffer H, Gros P, Costa JL, Tartaglia M, van der Burgt I, Yntema HG, den Hertog J. Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2015;<span class="ref-vol">23</span>:317–24.</span> [<a href="/pmc/articles/PMC4326711/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4326711</span></a>] [<a href="/pubmed/24939586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24939586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wes.1996.5839">Wes PD, Yu M, Montell C. RIC, a calmodulin-binding Ras-like GTPase. <span><span class="ref-journal">EMBO J. </span>1996;<span class="ref-vol">15</span>:5839–48.</span> [<a href="/pmc/articles/PMC452332/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC452332</span></a>] [<a href="/pubmed/8918462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8918462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wilkinson.2012.442">Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, Towbin JA, Connuck DM, Messere JE, Lipshultz SE. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. <span><span class="ref-journal">Am Heart J. </span>2012;<span class="ref-vol">164</span>:442–8.</span> [<a href="/pubmed/22980313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22980313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wingbermuehle.2009.15">Wingbermuehle E, Egger J, van der Burgt I, Verhoeven W. Neuropsychological and behavioral aspects of Noonan syndrome. <span><span class="ref-journal">Horm Res. </span>2009;<span class="ref-vol">72</span> Suppl 2:15–23.</span> [<a href="/pubmed/20029232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20029232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.wolvius.2006.1289">Wolvius EB, de Lange J, Smeets EE, van der Wal KG, van den Akker HP. Noonan-like/multiple giant cell lesion syndrome: report of a case and review of the literature. <span><span class="ref-journal">J Oral Maxillofac Surg. </span>2006;<span class="ref-vol">64</span>:1289–92.</span> [<a href="/pubmed/16860226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16860226</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yamamoto.2015.413">Yamamoto GL, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S, Abramowicz A, Cristian I, Buscarilli M, Naslavsky MS, Malaquias AC, Zatz M, Bodamer O, Majewski J, Jorge AA, Pereira AC, Kim CA, Passos-Bueno MR, Bertola DR. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:413–21.</span> [<a href="/pubmed/25795793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25795793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yaoita.2016.209">Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A, Yokozawa M, Suzumura H, Nakahara A, Nakano Y, Hokosaki T, Ohmori A, Sawada H, Migita O, Mima A, Lapunzina P, Santos-Simarro F, Garc&#x000ed;a-Mi&#x000f1;a&#x000fa;r S, Ogata T, Kawame H, Kurosawa K, Ohashi H, Inoue S, Matsubara Y, Kure S, Aoki Y. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. <span><span class="ref-journal">Hum Genet. </span>2016;<span class="ref-vol">135</span>:209–22.</span> [<a href="/pubmed/26714497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26714497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yoon.2013.917">Yoon SR, Choi SK, Eboreime J, Gelb BD, Calabrese P, Arnheim N. Age-dependent germline mosaicism of the most common Noonan syndrome mutation shows the signature of germline selection. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:917–26.</span> [<a href="/pmc/articles/PMC3682763/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3682763</span></a>] [<a href="/pubmed/23726368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23726368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yoshida.2004a.3359">Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, Okuyama T, Horikawa R, Tanaka T, Ogata T. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004a;<span class="ref-vol">89</span>:3359–64.</span> [<a href="/pubmed/15240615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15240615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.yoshida.2004b.63">Yoshida R, Miyata M, Nagai T, Yamazaki T, Ogata T. A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. <span><span class="ref-journal">Am J Med Genet A. </span>2004b;<span class="ref-vol">128A</span>:63–6.</span> [<a href="/pubmed/15211660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15211660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zarate.2014.np13">Zarate YA, Lichty AW, Champion KJ, Clarkson LK, Holden KR, Matheus MG. Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutation. <span><span class="ref-journal">J Child Neurol. </span>2014;<span class="ref-vol">29</span>:NP13–7.</span> [<a href="/pubmed/23877478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23877478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zavras.2015.71">Zavras N, Meazza C, Pilotta A, Gertosio C, Pagani S, Tinelli C, Bozzola M. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency. <span><span class="ref-journal">Ital J Pediatr. </span>2015;<span class="ref-vol">41</span>:71.</span> [<a href="/pmc/articles/PMC4595189/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4595189</span></a>] [<a href="/pubmed/26444854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26444854</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zenker.2004.368">Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A. Genotype-phenotype correlations in Noonan syndrome. <span><span class="ref-journal">J Pediatr. </span>2004;<span class="ref-vol">144</span>:368–74.</span> [<a href="/pubmed/15001945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15001945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="noonan.REF.zenker.2007.131">Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:131–5.</span> [<a href="/pmc/articles/PMC2598066/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598066</span></a>] [<a href="/pubmed/17056636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17056636</span></a>]</div></li></ul></div></div><div id="noonan.Chapter_Notes"><h2 id="_noonan_Chapter_Notes_">Chapter Notes</h2><div id="noonan.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 August 2019 (ma) Revision: pathogenic variants in <i>LZTR1</i> associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Noonan syndrome</div></li><li class="half_rhythm"><div>25 February 2016 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 October 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 September 2007 (cd) Revision: mutations in <i>RAF1</i> associated with Noonan syndrome</div></li><li class="half_rhythm"><div>22 December 2006 (cd) Revision: <i>SOS1</i> mutations responsible for some cases of Noonan syndrome; clinical testing available</div></li><li class="half_rhythm"><div>22 May 2006 (cd) Revision: prenatal testing for Noonan syndrome caused by <i>KRAS</i> mutations clinically available</div></li><li class="half_rhythm"><div>16 May 2006 (cd) Revision: <i>KRAS</i> testing clinically available</div></li><li class="half_rhythm"><div>1 May 2006 (ja) Revision: mutations in <i>KRAS</i> cause Noonan syndrome</div></li><li class="half_rhythm"><div>9 March 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 December 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 November 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>2 August 2001 (ja) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1124</span><span class="label">PMID: <a href="/pubmed/20301303" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301303</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rp-overview/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/leopard/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1124&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1124/?report=reader">PubReader</a></li><li><a href="/books/NBK1124/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1124" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1124" style="display:none" title="Cite this Page"><div class="bk_tt">Allanson JE, Roberts AE. Noonan Syndrome. 2001 Nov 15 [Updated 2019 Aug 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1124/pdf/Bookshelf_NBK1124.pdf">PDF version of this page</a> (617K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#noonan.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#noonan.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#noonan.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#noonan.Genetically_Related_Allelic_Disor" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#noonan.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#noonan.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#noonan.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#noonan.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#noonan.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#noonan.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#noonan.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8216[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LZTR1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4893[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=673[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BRAF</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6654[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SOS1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5894[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RAF1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5781[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PTPN11</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5604[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MAP2K1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3845[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KRAS</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6016[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RIT1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1124+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1497174" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1497174" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1497174" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1497174" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301557" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome with Multiple Lentigines</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Noonan Syndrome with Multiple Lentigines<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gelb BD, Tartaglia M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301347" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Myasthenic Syndromes</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Myasthenic Syndromes<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Abicht A, Müller J S, Lochmüller H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301365" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cardiofaciocutaneous Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cardiofaciocutaneous Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rauen KA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26518681" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation-a review of the literature.</a><span class="source">[Eur J Pediatr. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation-a review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nemcikova M, Vejvalkova S, Fencl F, Sukova M, Krepelova A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Pediatr. 2016 Apr; 175(4):587-92. Epub 2015 Oct 31.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301303" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301303" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040d7339a66ee2ba5af7f0">Noonan Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Noonan Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:31:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A427DE04095610000000001A00096&amp;ncbi_session=CE8A427DE040D721_0416SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1124%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1124&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1124/&amp;ncbi_pagename=Noonan Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A427DE040D721_0416SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>